data_2n4c_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n4c _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.413 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.451 HG23 HD12 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.42 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.413 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.451 HD12 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.41 HD13 ' HA ' ' A' ' 52' ' ' ILE . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.533 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.542 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.413 HG23 HD12 ' A' ' 52' ' ' ILE . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.424 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.4 HG11 HG12 ' A' ' 52' ' ' ILE . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.436 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.436 HD13 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.402 ' HB ' ' SD ' ' A' ' 10' ' ' MET . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' MET . . . . . 0.402 ' SD ' ' HB ' ' A' ' 7' ' ' VAL . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.564 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.412 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.412 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.564 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.402 ' HB ' ' SD ' ' A' ' 10' ' ' MET . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' MET . . . . . 0.402 ' SD ' ' HB ' ' A' ' 7' ' ' VAL . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.564 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.412 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.412 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.564 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt . . . . . 0 CA--C 1.527 0.071 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.499 HG12 ' HB2' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.42 HG23 HD12 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.43 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.43 HD13 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt . . . . . 0 N--CA 1.46 0.059 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.452 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.452 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.501 HG12 ' HB2' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 52' ' ' ILE . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.406 HG11 HG12 ' A' ' 52' ' ' ILE . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.431 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.431 HD13 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.501 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.46 0.045 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.544 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.48 HG12 ' HB2' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.48 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.527 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.465 HG12 ' HB2' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.458 ' O ' HG23 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.817 ' O ' HG21 ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.527 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.465 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.55 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp . . . . . 0 N--CA 1.46 0.057 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.511 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.436 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.481 ' HA ' ' HB1' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.481 ' HB1' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.511 ' HB1' ' HB2' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.55 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.436 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.438 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' MET . . . . . 0.426 ' HE2' ' HB2' ' A' ' 34' ' ' ALA . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.418 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.459 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.426 ' HB2' ' HE2' ' A' ' 10' ' ' MET . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.438 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.5 ' HA ' HD13 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.42 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 81.8 p . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.444 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.044 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.411 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.411 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.444 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.441 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.455 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.405 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . 0.412 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.499 ' HA ' HD13 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.556 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.029 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.426 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . 0.426 ' HB1' ' HB2' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.556 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.416 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.449 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' MET . . . . . 0.449 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . 0.442 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.442 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.401 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 32' ' ' VAL . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.466 ' HB3' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 23' ' ' ILE . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.401 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.588 HD13 ' HB2' ' A' ' 49' ' ' ALA . 41.9 tp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.616 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . 0.588 ' HB2' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.616 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.49 HD13 HD11 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.409 HG22 HD11 ' A' ' 19' ' ' ILE . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' MET . . . . . 0.404 ' SD ' ' HB3' ' A' ' 36' ' ' PRO . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.5 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 7' ' ' VAL . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.427 ' HB2' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . 0.5 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.427 HG13 ' HB2' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.422 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.3 -138.11 10.07 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt -99.28 150.16 22.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.533 HG12 ' HB2' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.413 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.451 HG23 HD12 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.42 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.413 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.451 HD12 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.41 HD13 ' HA ' ' A' ' 52' ' ' ILE . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.533 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t -149.84 143.7 16.97 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -69.05 -16.39 40.49 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 112.367 175.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 179.103 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.873 0.368 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.38 -141.73 12.1 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.553 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt -103.46 142.86 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.542 HG12 ' HB2' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.542 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t -146.0 142.54 17.89 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -67.9 -16.31 45.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.713 2.275 . . . . 0.0 112.308 174.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.802 -179.795 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.887 0.375 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.77 -140.03 10.73 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.568 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt -97.96 145.05 26.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.413 HG23 HD12 ' A' ' 52' ' ' ILE . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.424 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.4 HG11 HG12 ' A' ' 52' ' ' ILE . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.436 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.436 HD13 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.4 141.94 18.77 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -69.06 -15.26 39.55 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.654 2.236 . . . . 0.0 112.318 174.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.952 179.749 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.402 ' HB ' ' SD ' ' A' ' 10' ' ' MET . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' MET . . . . . 0.402 ' SD ' ' HB ' ' A' ' 7' ' ' VAL . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.564 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.412 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.412 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.564 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.402 ' HB ' ' SD ' ' A' ' 10' ' ' MET . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' MET . . . . . 0.402 ' SD ' ' HB ' ' A' ' 7' ' ' VAL . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.564 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.412 ' HG3' ' HB ' ' A' ' 32' ' ' VAL . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.412 ' HB ' ' HG3' ' A' ' 20' ' ' LYS . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.564 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 -0.052 0 CA-C-O 120.851 0.358 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.7 -140.28 10.89 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.45 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.11 144.53 26.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.499 HG12 ' HB2' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.42 HG23 HD12 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.43 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.43 HD13 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.499 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -144.41 142.08 18.97 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -68.79 -15.58 40.8 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.618 2.212 . . . . 0.0 112.353 174.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.912 179.814 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.052 0 CA-C-O 120.838 0.352 . . . . 0.0 111.131 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.03 -140.49 11.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt -99.41 141.2 32.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.452 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.452 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.506 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t -151.88 140.9 13.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.24 -15.67 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.695 2.264 . . . . 0.0 112.37 174.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.988 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.032 0 CA-C-O 120.874 0.369 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.74 -140.24 10.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.5 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -97.52 144.8 26.85 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.501 HG12 ' HB2' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 52' ' ' ILE . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.419 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.419 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.406 HG11 HG12 ' A' ' 52' ' ' ILE . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.431 ' HA ' HD13 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.431 HD13 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.501 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.52 141.9 18.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -68.84 -15.48 40.53 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.662 2.241 . . . . 0.0 112.355 174.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.763 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.891 0.377 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -142.03 12.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.42 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt -102.85 141.85 34.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.544 HG12 ' HB2' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.544 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -145.38 142.68 18.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -67.98 -16.08 44.6 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.737 2.291 . . . . 0.0 112.248 174.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.84 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.459 -0.022 0 CA-C-O 120.876 0.37 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.02 -152.89 29.84 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.505 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt -103.37 139.2 39.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.412 ' HB2' ' HA ' ' A' ' 63' ' ' PRO . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.48 HG12 ' HB2' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.48 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t -145.74 142.67 18.23 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.412 ' HA ' ' HB2' ' A' ' 8' ' ' GLU . 68.8 Cg_endo -68.91 -15.59 40.37 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.341 174.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 179.932 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.834 0.349 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.07 123.76 3.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.542 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt -124.21 149.97 45.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.527 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.465 HG12 ' HB2' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.458 ' O ' HG23 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.817 ' O ' HG21 ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.527 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.617 ' O ' ' HG3' ' A' ' 63' ' ' PRO . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.465 ' HB2' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.512 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -90.6 108.5 27.7 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.617 ' HG3' ' O ' ' A' ' 53' ' ' ALA . 83.3 Cg_endo -81.13 -17.31 9.32 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.337 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.835 -178.595 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.96 114.97 0.39 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 -177.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.55 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp -93.65 135.71 34.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 -178.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.424 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.511 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.436 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.481 ' HA ' ' HB1' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.481 ' HB1' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.511 ' HB1' ' HB2' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.55 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.436 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.426 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 66.8 p -134.79 159.2 73.03 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.426 ' HD2' ' HB ' ' A' ' 62' ' ' THR . 81.4 Cg_endo -70.44 157.35 59.34 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.71 2.274 . . . . 0.0 112.302 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.849 177.613 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.812 0.339 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.02 115.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.463 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.438 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp -105.38 140.06 39.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 -179.095 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.459 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' MET . . . . . 0.426 ' HE2' ' HB2' ' A' ' 34' ' ' ALA . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.42 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.418 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.459 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.426 ' HB2' ' HE2' ' A' ' 10' ' ' MET . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.438 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.5 ' HA ' HD13 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.5 HD13 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.42 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.465 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 81.8 p -131.26 160.43 67.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.465 ' HD2' ' HB ' ' A' ' 62' ' ' THR . 79.2 Cg_endo -68.8 160.3 50.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.714 2.276 . . . . 0.0 112.313 170.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 178.475 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.541 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.444 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -102.05 139.98 36.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.411 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.411 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.441 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.437 ' HB3' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.444 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.441 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -109.22 115.23 56.89 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.81 155.03 48.93 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.283 177.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.448 ' O ' ' HG2' ' A' ' 64' ' ' GLU . 88.7 tt0 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.902 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.831 0.348 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.94 115.02 0.39 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.507 -178.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt -110.04 147.46 33.51 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.455 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.405 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . 0.412 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.499 ' HA ' HD13 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.499 HD13 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m -116.72 119.83 35.1 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.71 152.58 59.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.342 177.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.86 -178.814 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.065 0 CA-C-O 120.787 0.327 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.99 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.435 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.556 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -97.96 136.66 37.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.522 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.402 ' HA ' ' HA ' ' A' ' 63' ' ' PRO . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.426 ' HB2' ' HB1' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . 0.426 ' HB1' ' HB2' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.556 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m -116.08 120.25 35.61 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.402 ' HA ' ' HA ' ' A' ' 7' ' ' VAL . 70.0 Cg_endo -71.39 154.97 60.75 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.72 2.28 . . . . 0.0 112.328 177.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.42 ' O ' ' HG2' ' A' ' 64' ' ' GLU . 88.4 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.8 0.333 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.99 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.566 177.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.416 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp -108.52 141.98 39.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 -178.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.449 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' MET . . . . . 0.449 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . 0.442 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.442 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.401 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 32' ' ' VAL . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.466 ' CG1' ' HB3' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.466 ' HB3' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.405 HG22 HD13 ' A' ' 23' ' ' ILE . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.416 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.401 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m -137.19 131.33 17.64 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.71 154.97 72.61 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.731 2.287 . . . . 0.0 112.276 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.881 -178.943 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.771 0.32 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.05 125.06 3.93 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.512 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.588 HD13 ' HB2' ' A' ' 49' ' ' ALA . 41.9 tp -134.45 128.21 33.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.69 ' HA ' ' HB3' ' A' ' 63' ' ' PRO . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.616 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.588 ' HB2' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.616 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.49 HD13 HD11 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p -125.08 75.03 67.39 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.69 ' HB3' ' HA ' ' A' ' 7' ' ' VAL . 72.4 Cg_endo -75.02 71.29 5.07 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.727 2.285 . . . . 0.0 112.398 177.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 -178.83 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.802 0.335 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 106.19 121.29 4.78 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.527 -178.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt -120.55 150.8 40.29 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 -176.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.409 HG22 HD11 ' A' ' 19' ' ' ILE . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' MET . . . . . 0.404 ' SD ' ' HB3' ' A' ' 36' ' ' PRO . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.5 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.409 HD11 HG22 ' A' ' 7' ' ' VAL . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.427 ' HB2' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.5 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.427 HG13 ' HB2' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.556 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m -99.91 98.24 7.09 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.556 ' HD3' ' O ' ' A' ' 61' ' ' TYR . 93.1 Cg_endo -81.12 124.31 4.85 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.892 170.11 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.857 0.36 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.92 55.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.49 -177.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.422 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt -93.21 138.55 31.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 178.536 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.432 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.426 ' O ' HG13 ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.422 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p -115.96 155.53 47.76 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.432 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 73.4 Cg_endo -77.49 -8.94 17.36 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.247 . . . . 0.0 112.369 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.855 -177.652 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.518 HG12 ' HB1' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.411 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.518 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.522 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.522 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.483 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.419 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt . . . . . 0 CA--C 1.527 0.071 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.482 HG12 ' HB1' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.412 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.412 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.482 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt . . . . . 0 N--CA 1.46 0.059 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.491 HG12 ' HB1' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.435 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.491 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.484 HG12 ' HB1' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.412 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.413 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.413 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.484 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.46 0.045 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.525 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.525 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.464 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.512 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.447 HG12 ' HB1' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.811 HG23 ' O ' ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.512 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.447 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp . . . . . 0 N--CA 1.46 0.057 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.494 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.421 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.461 ' HA ' ' HB3' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.461 ' HB3' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.494 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.534 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.421 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' MET . . . . . 0.414 ' HE1' HG22 ' A' ' 41' ' ' VAL . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.412 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.403 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.403 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' HE1' ' A' ' 10' ' ' MET . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.486 ' HA ' HD12 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.486 HD12 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.412 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 81.8 p . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.432 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.044 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.402 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.429 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.439 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.482 ' HA ' HD12 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.029 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.411 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.406 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.438 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' MET . . . . . 0.438 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.433 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.456 ' CG1' ' HB2' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.456 ' HB2' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.571 HD13 ' HB1' ' A' ' 49' ' ' ALA . 41.9 tp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.606 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ALA . . . . . 0.571 ' HB1' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.606 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.475 HD12 HD13 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.488 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB1' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . 0.488 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.41 HG13 ' HB1' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.405 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.3 -138.11 10.07 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt -99.28 150.16 22.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.518 HG12 ' HB1' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.411 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.518 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t -149.84 143.7 16.97 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -69.05 -16.39 40.49 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 112.367 175.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 179.103 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.873 0.368 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.38 -141.73 12.1 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.553 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt -103.46 142.86 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.522 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.522 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t -146.0 142.54 17.89 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -67.9 -16.31 45.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.713 2.275 . . . . 0.0 112.308 174.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.802 -179.795 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.887 0.375 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.77 -140.03 10.73 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.568 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt -97.96 145.05 26.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.483 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.419 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.4 141.94 18.77 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -69.06 -15.26 39.55 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.654 2.236 . . . . 0.0 112.318 174.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.952 179.749 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 -0.052 0 CA-C-O 120.851 0.358 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.7 -140.28 10.89 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.45 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.11 144.53 26.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.482 HG12 ' HB1' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.412 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.412 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.482 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -144.41 142.08 18.97 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -68.79 -15.58 40.8 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.618 2.212 . . . . 0.0 112.353 174.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.912 179.814 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.052 0 CA-C-O 120.838 0.352 . . . . 0.0 111.131 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.03 -140.49 11.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt -99.41 141.2 32.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.491 HG12 ' HB1' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.435 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.491 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t -151.88 140.9 13.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.24 -15.67 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.695 2.264 . . . . 0.0 112.37 174.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.988 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.032 0 CA-C-O 120.874 0.369 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.74 -140.24 10.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.5 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -97.52 144.8 26.85 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.484 HG12 ' HB1' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.412 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.413 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.413 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.484 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.52 141.9 18.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -68.84 -15.48 40.53 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.662 2.241 . . . . 0.0 112.355 174.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.763 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.891 0.377 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -142.03 12.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.42 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt -102.85 141.85 34.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.525 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.525 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -145.38 142.68 18.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -67.98 -16.08 44.6 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.737 2.291 . . . . 0.0 112.248 174.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.84 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.459 -0.022 0 CA-C-O 120.876 0.37 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.02 -152.89 29.84 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.505 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt -103.37 139.2 39.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.464 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t -145.74 142.67 18.23 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -68.91 -15.59 40.37 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.341 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 179.932 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.834 0.349 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.07 123.76 3.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.542 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt -124.21 149.97 45.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.512 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.447 HG12 ' HB1' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.811 HG23 ' O ' ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.512 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.607 ' O ' ' HG3' ' A' ' 63' ' ' PRO . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.447 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.504 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -90.6 108.5 27.7 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.607 ' HG3' ' O ' ' A' ' 53' ' ' ALA . 83.3 Cg_endo -81.13 -17.31 9.32 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.337 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.835 -178.595 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.96 114.97 0.39 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 -177.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp -93.65 135.71 34.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 -178.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.435 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.494 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.421 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.461 ' HA ' ' HB3' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.461 ' HB3' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.494 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.534 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.421 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.414 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 66.8 p -134.79 159.2 73.03 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.435 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 81.4 Cg_endo -70.44 157.35 59.34 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.71 2.274 . . . . 0.0 112.302 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.849 177.613 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.812 0.339 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.02 115.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.463 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp -105.38 140.06 39.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 -179.095 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.47 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' MET . . . . . 0.414 ' HE1' HG22 ' A' ' 41' ' ' VAL . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.412 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.403 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.403 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' HE1' ' A' ' 10' ' ' MET . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.486 ' HA ' HD12 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.486 HD12 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.412 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . 0.45 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 81.8 p -131.26 160.43 67.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.47 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 79.2 Cg_endo -68.8 160.3 50.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.714 2.276 . . . . 0.0 112.313 170.012 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 178.475 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.541 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.432 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -102.05 139.98 36.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.402 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.429 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -109.22 115.23 56.89 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.81 155.03 48.93 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.283 177.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 64' ' ' GLU . 88.7 tt0 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.902 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.831 0.348 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.94 115.02 0.39 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.507 -178.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt -110.04 147.46 33.51 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.439 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.482 ' HA ' HD12 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m -116.72 119.83 35.1 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.71 152.58 59.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.342 177.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.86 -178.814 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.065 0 CA-C-O 120.787 0.327 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.99 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.435 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -97.96 136.66 37.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.522 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.411 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m -116.08 120.25 35.61 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -71.39 154.97 60.75 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.72 2.28 . . . . 0.0 112.328 177.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . 0.415 ' O ' ' HG2' ' A' ' 64' ' ' GLU . 88.4 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.8 0.333 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.99 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.566 177.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.406 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp -108.52 141.98 39.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 -178.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.438 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' MET . . . . . 0.438 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.433 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.456 ' CG1' ' HB2' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.456 ' HB2' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m -137.19 131.33 17.64 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.71 154.97 72.61 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.731 2.287 . . . . 0.0 112.276 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.881 -178.943 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.771 0.32 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.05 125.06 3.93 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.512 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.571 HD13 ' HB1' ' A' ' 49' ' ' ALA . 41.9 tp -134.45 128.21 33.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.672 ' HA ' ' HB3' ' A' ' 63' ' ' PRO . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.606 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.571 ' HB1' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.606 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.475 HD12 HD13 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p -125.08 75.03 67.39 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.672 ' HB3' ' HA ' ' A' ' 7' ' ' VAL . 72.4 Cg_endo -75.02 71.29 5.07 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.727 2.285 . . . . 0.0 112.398 177.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 -178.83 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.802 0.335 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 106.19 121.29 4.78 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.527 -178.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt -120.55 150.8 40.29 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 -176.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.488 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB1' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.488 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.41 HG13 ' HB1' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.548 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m -99.91 98.24 7.09 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.548 ' HD3' ' O ' ' A' ' 61' ' ' TYR . 93.1 Cg_endo -81.12 124.31 4.85 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.892 170.11 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.857 0.36 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.92 55.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.49 -177.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.405 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt -93.21 138.55 31.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 178.536 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.44 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' O ' ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p -115.96 155.53 47.76 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.44 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 73.4 Cg_endo -77.49 -8.94 17.36 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.247 . . . . 0.0 112.369 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.855 -177.652 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.518 HG12 ' HB1' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.411 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.518 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.522 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.522 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t . . . . . 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.483 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.419 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 N--CA 1.46 0.069 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt . . . . . 0 CA--C 1.527 0.071 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.482 HG12 ' HB1' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.412 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.412 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.482 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt . . . . . 0 N--CA 1.46 0.059 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.491 HG12 ' HB1' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.435 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.491 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t . . . . . 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt . . . . . 0 C--O 1.23 0.055 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.484 HG12 ' HB1' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.412 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.413 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.413 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.484 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt . . . . . 0 N--CA 1.46 0.045 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.525 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.525 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.464 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t . . . . . 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.512 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.447 HG12 ' HB1' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.811 HG23 ' O ' ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.512 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.447 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m . . . . . 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp . . . . . 0 N--CA 1.46 0.057 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.494 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.421 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.461 ' HA ' ' HB3' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.461 ' HB3' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.494 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.534 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.421 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 66.8 p . . . . . 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . 0.414 ' HE1' HG22 ' A' ' 41' ' ' VAL . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.412 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.403 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.403 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' HE1' ' A' ' 10' ' ' MET . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.486 ' HA ' HD12 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.486 HD12 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.412 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 81.8 p . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.432 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.044 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.402 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.429 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m . . . . . 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt . . . . . 0 CA--C 1.526 0.043 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.439 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.482 ' HA ' HD12 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp . . . . . 0 N--CA 1.46 0.029 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.411 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.406 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp . . . . . 0 CA--C 1.527 0.059 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.438 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . 0.438 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.433 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.456 ' CG1' ' HB2' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.456 ' HB2' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.571 HD13 ' HB1' ' A' ' 49' ' ' ALA . 41.9 tp . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.606 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . 0.571 ' HB1' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.606 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.475 HD12 HD13 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p . . . . . 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.488 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB1' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . 0.488 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.41 HG13 ' HB1' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m . . . . . 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.405 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p . . . . . 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.058 0 CA-C-O 120.845 0.355 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.3 -138.11 10.07 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 86.2 mt -99.28 150.16 22.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.825 0.345 . . . . 0.0 110.926 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.6 t -130.1 129.97 44.24 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.812 178.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -130.26 127.73 40.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.822 178.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 t60 -99.84 120.84 40.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.813 178.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 66.5 t -116.21 125.02 73.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 -170.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 73.6 mm-40 -71.31 -36.5 71.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.851 -176.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -71.33 -18.37 62.39 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.897 -172.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -74.01 112.62 10.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.887 177.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 72.2 p -133.47 -12.45 2.72 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.175 177.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.1 p -154.98 173.56 16.38 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.858 -178.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.98 -14.99 62.02 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.472 -174.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -74.2 -14.37 60.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.767 0.318 . . . . 0.0 110.792 -179.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.2 m -94.87 -43.13 8.34 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.906 175.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.44 -40.94 98.49 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.157 -179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -63.66 -42.67 98.64 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.508 -177.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.518 HG12 ' HB1' ' A' ' 59' ' ' ALA . 69.4 t -66.9 -42.64 89.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.824 0.345 . . . . 0.0 111.169 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.0 mt -61.56 -45.03 99.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.182 178.197 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 55.2 tttp -61.13 -42.13 97.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 179.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.04 -41.03 97.42 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.478 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.96 -43.02 97.04 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.754 0.311 . . . . 0.0 111.083 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.438 HG23 HD11 ' A' ' 52' ' ' ILE . 90.2 mt -64.81 -49.91 77.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -65.06 -35.39 81.01 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.86 -176.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -68.11 -44.11 76.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.899 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.6 p -89.83 -19.36 24.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.16 -173.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.411 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 57.4 t -127.76 108.02 20.49 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.549 0.69 . . . . 0.0 111.179 177.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 53.2 Cg_endo -70.18 134.78 27.88 Favored 'Trans proline' 0 C--O 1.231 0.125 0 C-N-CA 122.677 2.252 . . . . 0.0 112.347 -177.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.29 20.49 78.88 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.446 178.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.55 133.61 35.4 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.797 0.332 . . . . 0.0 111.07 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.69 121.82 41.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.086 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 63.9 t -122.8 120.98 62.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.127 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -116.87 103.87 10.74 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.872 169.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.61 138.53 46.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.103 -172.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 60.4 t0 -131.95 105.33 13.9 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.659 0.742 . . . . 0.0 110.843 177.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -77.28 -22.95 10.64 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.713 2.276 . . . . 0.0 112.304 -176.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.46 -34.92 76.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.107 171.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 66.9 m -94.19 -5.65 46.54 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.804 173.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 57.0 mtp180 59.99 30.02 19.55 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.951 175.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.9 m -135.23 140.37 45.2 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.127 -172.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -115.89 129.72 71.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.158 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 91.2 t -104.16 126.12 58.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.176 173.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.2 t -121.21 130.93 74.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.114 -169.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.28 -151.39 15.16 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.47 178.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.36 113.8 4.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.461 -177.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.7 m -143.74 174.28 4.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.752 0.31 . . . . 0.0 111.101 -179.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.416 ' O ' ' C ' ' A' ' 48' ' ' ASP . 93.9 p -62.63 -179.99 0.3 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.929 175.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.416 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.0 t0 -39.02 133.79 1.12 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.832 -174.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.38 -32.84 57.94 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.106 -177.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.55 -40.63 97.48 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 174.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 17.5 t-160 -68.81 -45.86 70.13 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.9 -177.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.438 HD11 HG23 ' A' ' 23' ' ' ILE . 11.2 tp -67.81 -29.1 43.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.091 -176.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.08 -38.66 91.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.038 172.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -69.36 -35.16 75.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.883 174.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.0 mt -65.54 -40.74 89.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.192 177.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.0 mt -62.84 -43.79 99.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.224 173.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 52.8 m -63.88 -32.21 73.65 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.104 175.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -19.45 65.82 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.043 -178.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.518 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -77.31 -6.58 53.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.114 178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.58 1.56 74.15 Favored Glycine 0 N--CA 1.453 -0.221 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.478 -179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -120.01 109.77 15.89 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.917 0.389 . . . . 0.0 110.935 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 10.3 t -149.84 143.7 16.97 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.544 0.688 . . . . 0.0 111.099 -172.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -69.05 -16.39 40.49 Favored 'Trans proline' 0 N--CA 1.465 -0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 112.367 175.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.872 179.103 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.059 0 CA-C-O 120.873 0.368 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.38 -141.73 12.1 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.553 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 75.1 mt -103.46 142.86 33.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.768 0.318 . . . . 0.0 110.869 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.7 t -122.62 130.39 52.94 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.815 178.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -137.52 128.03 26.66 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.801 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -97.35 129.15 44.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.861 -174.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.31 115.74 45.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.133 -177.047 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.91 -29.69 66.93 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.816 -174.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -72.54 -14.41 61.63 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.912 -172.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 89.4 mtp -65.54 132.85 49.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.802 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 75.0 m -125.01 -58.45 1.47 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.125 -0.488 . . . . 0.0 111.159 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.47 -179.13 5.55 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.913 -177.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.06 -18.3 57.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.498 -175.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -75.41 -22.38 57.47 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.734 0.302 . . . . 0.0 110.841 178.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 90.4 m -90.25 -38.79 13.18 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.862 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -36.51 84.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.104 176.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.37 -37.69 95.05 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.461 -179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.522 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -64.68 -42.49 95.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.826 0.346 . . . . 0.0 111.085 179.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.5 mt -62.11 -45.01 99.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.028 176.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.3 tttt -59.4 -42.92 92.87 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.902 178.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.88 -40.85 98.76 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.445 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.67 -41.62 98.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.773 0.32 . . . . 0.0 111.163 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 93.7 mt -64.6 -49.33 80.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.155 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.02 -36.19 83.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -65.22 -46.24 81.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.859 -177.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -91.22 -19.9 22.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.127 -173.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -130.82 101.74 16.69 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.57 0.7 . . . . 0.0 111.11 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.67 135.86 29.23 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 122.64 2.226 . . . . 0.0 112.322 -178.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.94 8.4 82.48 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.448 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.87 132.3 39.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.747 0.308 . . . . 0.0 111.084 -178.364 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.4 120.97 36.56 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.108 173.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.0 t -117.32 120.3 64.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 -175.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -117.74 104.01 10.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.872 170.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.6 140.31 47.47 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.015 -172.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.1 t0 -130.06 105.03 16.59 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.676 0.751 . . . . 0.0 110.901 175.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -77.48 -22.33 10.85 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 112.359 -176.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.65 -35.23 76.99 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.099 171.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.2 m -95.64 -5.04 43.32 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.754 173.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.9 mtm180 58.88 32.6 22.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.879 174.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.0 m -133.98 138.09 45.21 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.119 -0.492 . . . . 0.0 111.065 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.6 t -115.36 129.41 71.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.138 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.2 t -108.98 125.17 66.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.132 174.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.4 t -121.24 133.97 66.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.088 -173.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -162.67 6.45 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.565 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.46 112.74 3.22 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.465 -176.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 30.2 m -143.57 179.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.806 0.336 . . . . 0.0 111.105 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 87.5 p -57.08 173.04 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.927 176.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -40.62 140.23 0.71 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.906 -172.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.02 -34.31 59.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.082 -175.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.96 95.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.154 176.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 49.4 t-80 -70.01 -42.71 72.66 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.803 -174.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -68.53 -30.22 46.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.081 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.92 -39.45 93.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.111 173.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.86 -36.91 85.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.927 174.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.1 mt -64.94 -40.21 88.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.16 176.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.8 mt -63.72 -44.81 98.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.144 176.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -71.06 -25.01 62.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.12 178.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.02 -18.88 65.68 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.034 177.155 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.522 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.54 -3.74 45.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.087 178.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.39 4.91 63.91 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.48 179.199 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -118.51 117.0 27.82 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.973 0.416 . . . . 0.0 110.949 178.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.4 t -146.0 142.54 17.89 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-O 121.57 0.7 . . . . 0.0 111.122 -174.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -67.9 -16.31 45.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.713 2.275 . . . . 0.0 112.308 174.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.802 -179.795 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.049 0 CA-C-O 120.887 0.375 . . . . 0.0 111.152 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.77 -140.03 10.73 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.568 179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 84.1 mt -97.96 145.05 26.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.859 0.362 . . . . 0.0 110.884 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 44.6 t -125.85 129.47 49.45 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.814 176.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.3 t80 -137.0 124.88 22.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.871 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.2 t60 -96.63 130.01 43.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.857 -176.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.2 t -122.92 121.56 63.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.101 -177.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.07 -35.0 78.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.821 -176.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.03 -13.47 60.5 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.823 -167.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.5 mtp -65.05 132.26 48.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.839 -178.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 67.5 m -125.03 -57.89 1.49 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.177 -178.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.5 p -139.2 -178.83 5.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.899 -177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.39 -19.97 58.21 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.529 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -74.98 -21.23 59.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.765 0.317 . . . . 0.0 110.832 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 82.2 m -91.7 -39.36 11.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.88 174.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.36 -37.45 87.33 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.129 177.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -37.39 94.61 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.454 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.483 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.7 t -64.19 -41.87 93.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 120.9 0.381 . . . . 0.0 111.171 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.8 mt -61.87 -45.22 99.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.144 176.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -59.35 -40.66 87.11 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.849 177.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.44 -41.03 99.44 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.82 -41.37 97.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.756 0.312 . . . . 0.0 111.146 178.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.8 mt -64.51 -48.87 83.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.147 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.08 -37.14 83.46 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.911 -178.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.81 -42.68 99.33 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.861 -177.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.3 p -91.09 -22.81 20.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.112 -177.457 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.414 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.4 t -132.58 96.41 18.8 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.615 0.721 . . . . 0.0 111.176 176.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.2 Cg_endo -68.94 135.32 32.11 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.645 2.23 . . . . 0.0 112.402 -177.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.65 83.64 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.886 -0.673 . . . . 0.0 112.482 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.65 138.99 47.04 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.848 0.356 . . . . 0.0 110.999 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.31 120.32 33.46 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.116 174.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.5 t -122.06 120.7 62.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.213 -0.448 . . . . 0.0 111.13 -177.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.49 104.94 11.57 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.894 171.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.51 139.6 47.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.129 -172.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.08 104.85 16.61 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.581 0.705 . . . . 0.0 110.928 176.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -77.44 -22.19 11.03 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.666 2.244 . . . . 0.0 112.309 -175.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.44 -35.63 77.89 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.151 171.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.6 m -95.16 -5.06 44.89 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.821 173.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.8 mtm180 57.88 32.1 21.46 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.889 176.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.8 m -130.64 137.58 49.67 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.134 -174.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.2 t -114.38 129.51 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.157 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.7 t -105.81 125.06 61.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.21 174.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.8 t -119.35 129.7 74.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.127 -170.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -81.73 -153.31 10.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.534 178.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.07 114.83 4.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.441 -176.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.6 m -144.49 174.42 3.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.774 0.321 . . . . 0.0 111.149 178.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 85.9 p -61.14 -179.88 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.855 174.376 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.9 t0 -38.38 131.04 1.24 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.862 -174.296 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.49 -31.49 56.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.098 -177.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.62 -41.34 98.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.143 174.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.3 m170 -70.08 -42.82 72.26 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.884 -176.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.419 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.7 tp -70.26 -29.02 37.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.096 -176.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.86 -40.62 95.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.131 172.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -67.12 -36.34 81.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 174.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.419 HD12 ' HA ' ' A' ' 52' ' ' ILE . 80.5 mt -65.23 -39.93 87.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.197 177.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 85.2 mt -62.8 -44.94 99.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.192 175.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 70.2 p -70.98 -25.03 62.53 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.105 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.42 -18.18 65.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.073 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.483 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.3 -3.55 43.48 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.127 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.29 4.13 64.63 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.549 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -118.2 114.31 22.84 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.043 0.449 . . . . 0.0 110.91 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.4 141.94 18.77 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.613 0.72 . . . . 0.0 111.098 -173.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -69.06 -15.26 39.55 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.654 2.236 . . . . 0.0 112.318 174.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.952 179.749 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.028 0 CA-C-O 120.853 0.359 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -140.86 11.33 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.542 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -102.51 142.82 33.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.88 0.371 . . . . 0.0 110.855 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.0 t -123.16 130.59 52.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.842 177.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.6 t80 -136.9 129.61 30.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.867 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.4 t60 -98.48 129.63 45.07 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.853 -173.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.4 t -124.73 116.28 46.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.102 -177.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.75 -29.93 67.4 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.849 -174.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -72.15 -15.3 61.97 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -172.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.9 mtp -66.89 132.4 47.91 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.855 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 78.5 m -124.91 -57.55 1.52 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.193 -178.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -137.41 -179.19 5.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.876 -177.589 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.42 -19.39 57.61 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.46 -175.043 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.59 -21.39 57.86 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.735 0.302 . . . . 0.0 110.811 179.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 81.1 m -91.44 -39.53 11.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.9 174.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.47 -36.75 84.77 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.137 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.5 -36.88 93.8 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.424 -178.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.547 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.6 t -64.36 -43.7 97.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.187 -178.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.4 mt -62.39 -44.94 99.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.041 -0.527 . . . . 0.0 111.111 176.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.1 tttp -60.93 -42.58 98.41 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.934 179.322 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.61 96.91 Favored Glycine 0 C--N 1.331 0.298 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.487 178.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.57 98.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.724 0.297 . . . . 0.0 111.103 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.3 mt -65.3 -48.07 84.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.176 -179.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -64.59 -37.06 86.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.799 -177.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.38 -44.54 78.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.895 -178.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 74.2 p -88.82 -19.29 26.14 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.204 -174.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.82 102.02 16.52 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.554 0.692 . . . . 0.0 111.098 177.29 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.85 135.46 30.29 Favored 'Trans proline' 0 N--CA 1.465 -0.156 0 C-N-CA 122.643 2.229 . . . . 0.0 112.474 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 84.97 7.13 84.25 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.848 -0.692 . . . . 0.0 112.467 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.39 130.13 36.69 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.764 0.316 . . . . 0.0 111.107 -178.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -97.02 118.69 33.98 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.142 172.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.1 t -120.01 121.42 65.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.19 -176.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -115.95 106.73 14.12 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.84 171.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.69 139.97 45.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 -172.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -129.79 105.05 17.01 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.619 0.723 . . . . 0.0 110.892 177.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -77.19 -22.87 10.83 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 -176.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.18 -35.66 78.38 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.105 171.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.7 m -95.55 -5.06 43.57 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.839 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 58.37 32.24 21.85 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.983 175.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 61.8 m -133.64 138.95 46.18 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 116.081 -0.508 . . . . 0.0 111.119 -173.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.76 129.26 72.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.114 -179.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.1 t -109.12 125.17 66.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.162 175.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.0 t -122.57 134.19 66.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.072 -173.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.76 -160.35 5.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.472 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.57 114.02 4.4 Favored Glycine 0 C--N 1.331 0.262 0 C-N-CA 120.654 -0.784 . . . . 0.0 112.492 -175.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -144.56 177.43 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.818 0.342 . . . . 0.0 111.123 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 90.7 p -58.74 174.31 0.35 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 176.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.5 t70 -40.17 141.46 0.48 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.8 -171.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.15 -32.94 50.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.167 -176.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.26 -40.68 96.49 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 175.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.3 m170 -68.84 -42.87 76.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.912 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.8 tp -69.25 -30.91 47.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.094 178.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.31 -39.29 92.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.125 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -64.88 -36.93 85.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.861 175.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 90.9 mt -64.86 -40.19 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.175 175.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 88.7 mt -63.37 -44.66 99.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.247 176.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 77.4 p -71.0 -25.08 62.53 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.12 178.502 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.9 -18.86 65.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.081 177.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.547 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.75 -4.22 48.18 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.069 178.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.41 5.33 65.37 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.525 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -118.77 118.59 32.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.936 0.398 . . . . 0.0 110.898 178.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.8 t -145.9 142.6 18.03 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.573 0.702 . . . . 0.0 111.099 -175.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -67.91 -16.09 44.92 Favored 'Trans proline' 0 N--CA 1.465 -0.194 0 C-N-CA 122.682 2.255 . . . . 0.0 112.356 174.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.92 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 -0.052 0 CA-C-O 120.851 0.358 . . . . 0.0 111.118 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.7 -140.28 10.89 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.45 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.11 144.53 26.87 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.7 t -126.22 129.16 48.4 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.837 176.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.2 t80 -137.1 124.59 22.12 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.863 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.5 t60 -96.47 130.09 43.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.836 -176.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 97.5 t -123.11 121.52 63.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.074 -177.21 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.09 -34.92 78.67 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.89 -176.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -75.04 -13.38 60.49 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.927 -167.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 87.5 mtp -65.04 132.25 48.71 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.893 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.7 m -124.94 -58.38 1.48 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.23 -178.314 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -138.7 -178.91 5.52 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.987 -177.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.15 -18.67 58.17 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.449 -175.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -75.88 -20.99 57.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.75 0.31 . . . . 0.0 110.881 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 87.1 m -91.52 -39.5 11.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.903 174.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.35 -37.26 86.56 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.129 177.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.46 -37.53 94.82 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.826 -0.702 . . . . 0.0 112.534 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.482 HG12 ' HB1' ' A' ' 59' ' ' ALA . 75.8 t -64.44 -41.72 93.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 111.121 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -61.67 -45.07 99.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.072 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -60.1 -40.23 88.93 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.872 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.15 -40.98 99.79 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.494 178.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.05 -41.49 97.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.72 0.295 . . . . 0.0 111.091 178.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.402 HG23 HD11 ' A' ' 52' ' ' ILE . 92.6 mt -64.51 -48.87 83.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.091 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.9 tp10 -67.25 -37.22 83.14 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.823 -178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -61.66 -42.88 99.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.932 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.4 p -91.2 -22.5 20.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.134 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.41 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 50.6 t -132.65 96.39 18.66 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.506 0.67 . . . . 0.0 111.132 176.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 45.4 Cg_endo -69.05 135.17 31.41 Favored 'Trans proline' 0 C--N 1.341 0.132 0 C-N-CA 122.655 2.237 . . . . 0.0 112.361 -177.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.0 7.75 83.3 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.837 -0.697 . . . . 0.0 112.457 179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.9 48.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.799 0.333 . . . . 0.0 111.113 -179.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.57 120.95 34.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.11 174.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 64.3 t -123.14 120.66 61.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.114 -178.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.4 m-70 -117.93 104.86 11.32 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.854 170.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.36 139.94 47.5 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.154 -172.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.4 t0 -130.37 104.84 16.16 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.624 0.726 . . . . 0.0 110.919 176.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -77.38 -22.23 11.08 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.723 2.282 . . . . 0.0 112.291 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.34 -35.53 77.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.124 171.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.5 m -95.45 -4.98 44.09 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.825 173.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 64.8 mtm180 57.85 31.98 21.28 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.912 176.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.7 m -130.45 137.91 50.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.067 -174.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.0 t -114.32 129.41 70.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.184 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 92.2 t -105.39 125.49 60.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.21 174.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 66.9 t -119.72 130.64 73.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.085 -170.547 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.7 -151.42 11.77 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.5 178.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.58 113.93 4.71 Favored Glycine 0 N--CA 1.452 -0.237 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.439 -176.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 24.0 m -144.11 174.28 4.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.894 0.378 . . . . 0.0 111.045 179.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.427 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -60.98 -179.97 0.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.935 173.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.427 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.38 130.39 1.29 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.849 -174.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.36 -31.09 53.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.07 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -63.03 -41.44 99.52 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.097 174.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.1 m170 -70.07 -42.34 72.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.815 -176.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.412 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.4 tp -70.73 -29.1 36.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.083 -176.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.96 -40.8 95.55 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.096 172.581 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -66.85 -36.48 82.42 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.878 174.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.412 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.0 mt -65.04 -39.83 86.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.17 177.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.6 mt -62.49 -45.0 99.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.153 175.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.7 p -71.13 -25.11 62.43 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.086 178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.46 -18.11 65.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.012 178.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.482 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.42 -3.68 44.55 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.079 178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.57 4.46 63.92 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.484 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -118.45 113.99 22.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.917 0.389 . . . . 0.0 110.967 177.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -144.41 142.08 18.97 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.622 0.725 . . . . 0.0 111.089 -173.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -68.79 -15.58 40.8 Favored 'Trans proline' 0 C--N 1.342 0.226 0 C-N-CA 122.618 2.212 . . . . 0.0 112.353 174.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.912 179.814 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.052 0 CA-C-O 120.838 0.352 . . . . 0.0 111.131 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -98.03 -140.49 11.42 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.506 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 81.5 mt -99.41 141.2 32.49 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.87 0.367 . . . . 0.0 110.853 179.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.9 t -123.03 131.55 53.75 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.835 179.729 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 74.3 m-85 -129.7 136.15 49.34 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.834 178.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -110.13 124.7 52.01 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.781 171.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.96 122.45 64.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.157 -176.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -67.2 -35.16 79.03 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -175.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -73.79 -16.64 61.15 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.915 -167.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 97.4 mtp -66.13 131.11 45.41 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.846 -178.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 62.3 m -125.09 -58.32 1.47 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.234 -175.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.23 179.79 6.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.815 -175.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.29 -19.7 59.98 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.476 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -75.36 -19.78 59.38 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.723 0.296 . . . . 0.0 110.841 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 72.9 m -93.47 -40.01 10.57 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.946 175.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.65 -37.12 86.14 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.133 177.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.18 -35.36 91.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.565 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.491 HG12 ' HB1' ' A' ' 59' ' ' ALA . 73.6 t -64.05 -45.22 97.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.835 0.35 . . . . 0.0 111.169 -179.274 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.8 mt -63.05 -43.91 99.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.079 -0.509 . . . . 0.0 111.146 176.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -57.99 -46.3 85.43 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 178.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.59 -39.68 93.93 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.543 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.52 -44.06 97.3 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.766 0.317 . . . . 0.0 111.154 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.435 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.0 mt -66.53 -45.14 89.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.131 -179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -62.1 -40.44 95.86 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.886 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -67.44 -43.71 80.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.868 -175.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.1 p -90.65 -19.1 24.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.11 -173.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -129.01 102.35 19.12 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.51 0.672 . . . . 0.0 111.128 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -70.03 136.02 31.25 Favored 'Trans proline' 0 N--CA 1.466 -0.135 0 C-N-CA 122.744 2.296 . . . . 0.0 112.38 -178.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.19 5.73 85.24 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.485 179.447 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.02 127.59 32.95 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.879 0.371 . . . . 0.0 111.051 -178.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.97 117.26 30.77 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.062 171.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.9 t -118.61 122.86 70.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.156 -175.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.8 m-70 -114.88 105.2 12.73 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.848 174.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.18 136.41 48.71 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.07 -171.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 54.7 t0 -129.88 104.75 16.95 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.558 0.694 . . . . 0.0 110.868 174.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -77.18 -22.62 11.04 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.341 -175.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.79 -35.9 79.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.101 172.154 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.1 m -96.21 -4.99 41.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.789 174.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 73.1 mtm180 57.28 32.96 22.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.953 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 85.5 m -130.79 137.88 49.65 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.123 -173.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.5 t -120.1 128.59 75.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.16 178.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.1 t -111.17 124.34 67.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.165 175.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.9 t -119.95 133.21 67.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.105 -172.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -75.11 -161.22 8.8 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.532 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 112.36 3.14 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.493 -177.093 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.5 m -146.38 177.94 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.813 0.34 . . . . 0.0 111.093 -177.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 84.0 p -59.28 168.16 1.56 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.909 175.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -42.14 139.06 1.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.852 -172.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.91 -32.65 61.32 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.097 -177.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.79 -41.54 91.38 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.119 177.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 20.8 t-160 -63.95 -41.34 97.62 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.877 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.7 mm -64.68 -38.39 82.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.07 -38.15 89.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.022 177.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -66.82 -36.46 82.41 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.901 175.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.435 HG21 ' HA ' ' A' ' 23' ' ' ILE . 84.6 mt -64.85 -43.29 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.173 175.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.1 mt -60.73 -41.48 88.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.138 175.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 97.7 m -63.75 -37.95 89.27 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.08 173.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.78 -23.39 67.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.062 178.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.491 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.56 -6.5 55.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.113 176.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.21 9.76 61.65 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.481 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.1 m-85 -122.33 127.39 49.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.01 0.434 . . . . 0.0 110.898 -179.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 6.8 t -151.88 140.9 13.91 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.517 0.675 . . . . 0.0 111.116 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -69.24 -15.67 39.19 Favored 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.695 2.264 . . . . 0.0 112.37 174.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.887 179.988 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.032 0 CA-C-O 120.874 0.369 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.74 -140.24 10.87 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.814 -0.707 . . . . 0.0 112.5 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 83.8 mt -97.52 144.8 26.85 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.876 0.369 . . . . 0.0 110.855 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 45.2 t -125.88 129.17 48.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.807 176.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 60.7 t80 -137.09 124.71 22.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.873 -177.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -96.5 129.98 43.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.835 -176.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 94.4 t -122.99 121.42 63.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.161 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -67.08 -34.94 78.73 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.918 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -74.97 -13.44 60.52 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.88 -167.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 88.0 mtp -64.99 132.28 48.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.799 -178.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 63.3 m -125.01 -58.28 1.47 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.208 -178.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -138.8 -178.82 5.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.901 -177.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.97 58.68 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.745 -0.74 . . . . 0.0 112.46 -175.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.62 -21.18 57.98 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.698 0.285 . . . . 0.0 110.786 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.5 m -91.45 -39.48 11.94 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.848 174.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.38 -37.35 86.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.189 177.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.48 -37.48 94.75 Favored Glycine 0 N--CA 1.452 -0.26 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.472 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.484 HG12 ' HB1' ' A' ' 59' ' ' ALA . 74.9 t -64.28 -41.61 92.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.82 0.343 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.5 mt -61.74 -45.03 99.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.053 176.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -60.18 -40.25 89.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.844 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -63.3 -40.97 99.59 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.474 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.92 -41.56 97.62 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.679 0.276 . . . . 0.0 111.094 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.5 mt -64.47 -48.83 83.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.8 tp10 -67.11 -37.17 83.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.93 -178.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -61.61 -42.97 99.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.896 -177.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -91.11 -22.51 20.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.204 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.412 ' HA ' ' HD2' ' A' ' 28' ' ' PRO . 52.8 t -132.63 96.35 18.76 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.562 0.696 . . . . 0.0 111.142 176.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 27' ' ' VAL . 44.5 Cg_endo -69.0 135.22 31.67 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.642 2.228 . . . . 0.0 112.367 -177.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.09 7.68 83.1 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.401 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.41 139.87 48.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.799 0.333 . . . . 0.0 111.046 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.6 120.69 34.19 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.082 174.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 65.6 t -122.83 120.74 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.157 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -117.76 105.09 11.61 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.864 171.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -112.5 139.74 47.83 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.067 -172.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -130.09 104.81 16.61 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.641 0.734 . . . . 0.0 110.879 176.185 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -77.27 -22.31 11.17 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.723 2.282 . . . . 0.0 112.296 -175.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.39 -35.68 78.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.102 171.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.4 m -95.31 -4.91 44.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.859 173.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 65.0 mtm180 57.74 32.12 21.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.919 176.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 89.3 m -130.48 137.74 49.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.063 -174.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.7 t -114.33 129.56 70.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.141 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.3 t -105.73 125.36 61.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.188 174.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 67.0 t -119.55 129.89 74.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.103 -170.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.59 -152.04 10.57 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.504 178.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.91 114.34 4.83 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.439 -176.267 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 23.3 m -144.37 174.23 4.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.745 0.307 . . . . 0.0 111.174 178.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.428 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.1 p -61.19 -179.78 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.902 174.106 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.428 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.8 t0 -38.19 130.71 1.2 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.892 -174.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.39 -31.38 54.78 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.061 -177.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.88 -41.53 99.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.069 174.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 66.4 m170 -69.97 -42.59 72.93 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.852 -176.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.413 ' HA ' HD12 ' A' ' 55' ' ' ILE . 10.5 tp -70.53 -28.92 36.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.069 -176.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.79 95.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.084 172.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -66.97 -36.34 81.97 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.915 174.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.413 HD12 ' HA ' ' A' ' 52' ' ' ILE . 81.5 mt -65.18 -39.92 87.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.202 177.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 84.9 mt -62.67 -44.82 99.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.167 175.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 69.2 p -71.11 -25.0 62.4 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.093 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.37 -18.19 65.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.008 178.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.484 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.38 -3.77 44.85 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.105 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.39 64.15 Favored Glycine 0 N--CA 1.452 -0.243 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.5 179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -118.32 114.14 22.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 177.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.6 t -144.52 141.9 18.53 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.591 0.71 . . . . 0.0 111.118 -173.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 67.1 Cg_endo -68.84 -15.48 40.53 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.662 2.241 . . . . 0.0 112.355 174.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.763 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.064 0 CA-C-O 120.891 0.377 . . . . 0.0 111.137 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.92 -142.03 12.59 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.42 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.4 mt -102.85 141.85 34.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.926 0.393 . . . . 0.0 110.88 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.4 t -122.64 129.43 51.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.848 177.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 81.2 t80 -138.09 129.41 27.61 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.844 -178.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 66.0 t-80 -94.83 132.99 39.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.917 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.1 t -125.54 114.8 41.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.152 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -68.65 -29.62 68.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.833 -174.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.4 m-20 -72.85 -14.6 61.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.923 -172.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 96.6 mtp -66.52 131.79 46.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.897 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 79.2 m -124.98 -56.36 1.56 Allowed 'General case' 0 C--O 1.234 0.254 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.155 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.6 p -136.75 -179.54 5.76 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.899 -177.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.11 -18.76 58.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.521 -175.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -75.32 -21.93 58.06 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.708 0.29 . . . . 0.0 110.793 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -90.02 -38.53 13.54 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.889 174.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.46 -36.91 85.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.13 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.51 -37.92 95.49 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.478 -178.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.525 HG12 ' HB1' ' A' ' 59' ' ' ALA . 72.5 t -64.57 -42.97 96.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.813 0.339 . . . . 0.0 111.127 -179.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.8 mt -62.23 -44.9 99.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.103 176.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -59.04 -43.28 91.62 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.868 178.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.11 -40.84 98.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.544 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.68 -41.76 98.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.715 0.293 . . . . 0.0 111.054 179.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 92.4 mt -64.79 -48.94 82.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.128 -179.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -65.08 -37.53 87.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.849 -178.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -66.0 -44.68 84.09 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.835 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 77.0 p -90.53 -19.94 23.22 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.175 -174.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.7 t -131.96 100.51 15.82 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.582 0.706 . . . . 0.0 111.159 177.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.96 136.06 31.51 Favored 'Trans proline' 0 N--CA 1.465 -0.169 0 C-N-CA 122.678 2.252 . . . . 0.0 112.383 -178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.02 7.82 83.16 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.531 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -77.04 132.11 38.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.095 -178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.56 121.02 36.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.148 173.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 67.1 t -117.78 120.34 64.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.126 -175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.9 m-70 -117.74 105.74 12.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.882 170.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -110.98 140.27 45.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.174 -172.465 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 57.0 t0 -130.26 105.08 16.28 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.638 0.732 . . . . 0.0 110.816 177.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -76.98 -22.45 11.46 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.375 -175.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.23 -36.71 79.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.061 171.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 69.4 m -95.88 -4.86 42.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.779 175.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 69.1 mtm180 57.06 33.66 23.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 87.2 m -129.45 137.66 50.99 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.074 -173.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 68.6 t -114.84 127.53 72.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.178 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.0 t -108.68 125.12 65.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.21 175.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.8 t -121.94 133.82 67.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.083 -173.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.81 -161.02 5.76 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.825 -0.702 . . . . 0.0 112.534 179.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.86 113.41 3.93 Favored Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.442 -176.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -145.08 178.57 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.738 0.304 . . . . 0.0 111.128 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 90.1 p -56.92 172.8 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.934 176.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -40.6 140.3 0.69 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.812 -172.062 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.76 -34.61 59.54 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.081 -175.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -64.87 -41.09 95.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.111 176.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 50.3 t-80 -70.01 -42.97 72.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.817 -174.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.7 tp -68.18 -30.25 47.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.077 178.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.95 -39.69 93.88 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.144 173.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.05 -36.55 84.73 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 174.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 86.3 mt -64.88 -39.89 87.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.121 176.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 87.1 mt -63.08 -44.71 99.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.248 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 73.5 p -71.25 -25.12 62.34 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.078 178.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -18.45 65.31 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.051 177.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.525 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.4 -3.75 44.78 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.086 178.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.91 4.44 65.09 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.47 179.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -118.8 117.24 28.35 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.0 0.429 . . . . 0.0 110.95 177.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 8.5 t -145.38 142.68 18.51 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.584 0.707 . . . . 0.0 111.108 -174.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -67.98 -16.08 44.6 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.737 2.291 . . . . 0.0 112.248 174.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.84 -179.993 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.459 -0.022 0 CA-C-O 120.876 0.37 . . . . 0.0 111.086 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -95.02 -152.89 29.84 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.505 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 80.0 mt -103.37 139.2 39.08 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.851 0.358 . . . . 0.0 110.898 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.3 t -118.91 131.59 56.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.827 -178.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 77.0 t80 -135.82 129.29 32.2 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.867 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 83.7 t60 -97.47 130.83 44.53 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.842 -175.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.6 t -121.77 126.33 74.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.158 -178.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mm-40 -71.76 -36.82 70.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.904 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -67.34 -17.67 64.85 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.899 -175.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.5 mtp -74.25 114.73 12.95 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.875 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 81.1 p -136.06 -10.03 2.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.201 174.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -154.9 172.4 18.09 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.883 -177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.36 -14.91 62.75 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.483 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -73.55 -14.6 61.23 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.692 0.282 . . . . 0.0 110.849 -179.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 77.8 m -94.76 -43.96 8.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.874 174.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.26 -41.25 98.29 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.174 -178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.59 -43.15 96.91 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.497 -177.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.464 HG12 ' HB1' ' A' ' 59' ' ' ALA . 70.5 t -66.4 -42.82 91.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.859 0.361 . . . . 0.0 111.193 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.18 -45.59 98.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.081 -0.509 . . . . 0.0 111.101 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -60.04 -43.07 95.62 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.859 178.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -64.08 -40.48 98.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.449 178.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.48 -41.66 96.34 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.696 0.284 . . . . 0.0 111.044 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.7 mt -65.05 -46.64 90.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.177 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -65.22 -36.44 84.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.838 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -63.26 -43.57 97.61 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.856 -178.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 66.9 p -90.24 -23.29 21.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.154 -178.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -131.13 81.74 65.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.672 0.748 . . . . 0.0 111.126 176.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.81 137.16 40.92 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.623 2.216 . . . . 0.0 112.401 -178.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 -9.55 68.87 Favored Glycine 0 N--CA 1.452 -0.238 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.497 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.89 143.66 43.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.757 0.313 . . . . 0.0 111.076 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.99 118.18 31.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.126 174.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 66.6 t -119.57 122.87 69.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -176.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -116.39 105.97 13.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.896 174.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.8 137.84 46.08 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.044 -175.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -130.45 105.4 15.97 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.674 0.749 . . . . 0.0 110.817 -178.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -76.41 -24.26 10.83 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.659 2.24 . . . . 0.0 112.359 -177.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -68.03 -35.62 78.57 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.048 172.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.5 m -94.9 -6.14 43.29 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.895 174.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 59.68 31.21 20.75 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.899 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 88.3 m -134.8 140.99 46.3 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.151 -171.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 65.4 t -113.22 127.87 70.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.15 178.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.6 t -111.49 124.9 68.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.218 175.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.3 t -121.53 134.93 63.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.114 -173.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.14 -159.7 3.46 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.529 178.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.2 114.25 4.47 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.531 -173.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.5 m -144.02 175.07 3.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 111.071 178.514 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 48' ' ' ASP . 94.5 p -60.44 -179.85 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.897 176.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 47' ' ' SER . 10.3 t70 -40.64 140.91 0.62 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.762 -170.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.29 -31.93 55.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.117 -177.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.79 -39.92 95.72 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.145 175.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.7 m170 -67.81 -43.71 79.02 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.884 -175.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 10.9 tp -70.72 -30.29 41.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.78 -40.01 94.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.087 173.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.74 -36.42 83.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 175.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 89.6 mt -65.02 -39.89 87.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.136 176.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 89.0 mt -63.03 -44.74 99.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.169 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 67.6 p -71.3 -24.61 62.17 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.086 178.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.71 -19.46 65.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.023 177.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.464 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -78.87 -3.79 46.44 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.068 177.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.38 6.23 62.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.492 178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -120.1 116.67 26.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.927 0.394 . . . . 0.0 110.897 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 9.6 t -145.74 142.67 18.23 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.526 0.679 . . . . 0.0 111.135 -172.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -68.91 -15.59 40.37 Favored 'Trans proline' 0 N--CA 1.466 -0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.341 174.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 . . . . . 0 C--N 1.33 -0.26 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.812 179.932 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.834 0.349 . . . . 0.0 111.1 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.07 123.76 3.75 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.542 179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 79.1 mt -124.21 149.97 45.78 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 110.842 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.8 t -126.15 135.99 52.33 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.857 176.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.1 m-85 -129.76 143.53 50.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.892 -177.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -109.04 119.84 40.74 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.918 171.082 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -103.4 125.82 57.87 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.126 -173.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -77.0 -39.03 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.921 -172.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -82.39 -12.74 57.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.825 -171.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.4 ttm -63.97 119.92 11.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.958 -178.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 89.9 m -118.96 -43.53 2.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.039 -169.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.9 p -147.39 174.86 11.27 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.925 -172.039 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.512 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -56.01 -29.81 56.23 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.487 -175.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.3 t60 -59.83 -49.56 77.21 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.796 0.331 . . . . 0.0 110.932 175.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.4 m -64.88 -39.12 93.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.85 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.05 -38.43 91.03 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.04 175.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -41.04 97.45 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.413 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.447 HG12 ' HB1' ' A' ' 59' ' ' ALA . 66.0 t -64.34 -47.1 91.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 0.0 111.102 -179.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.31 -44.45 94.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.117 178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 46.1 tttp -56.35 -46.99 79.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.919 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.61 87.24 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.428 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -60.4 -43.54 96.57 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.819 0.343 . . . . 0.0 111.096 -176.152 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' HG22 ' A' ' 27' ' ' VAL . 96.7 mt -73.25 -50.25 32.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.191 177.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -54.08 -45.04 71.64 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.947 -171.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -65.87 -29.97 70.5 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.895 -178.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 42.0 p -95.21 -8.49 36.04 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.073 -172.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.811 HG23 ' O ' ' A' ' 27' ' ' VAL . 17.5 m -121.58 78.35 37.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 0.0 111.061 174.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 38.7 Cg_endo -65.34 131.77 29.29 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.644 2.229 . . . . 0.0 112.363 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.92 -19.48 53.82 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.448 -178.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.15 142.83 41.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.838 0.351 . . . . 0.0 111.115 -178.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 132.25 44.02 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.059 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.9 p -125.05 133.09 70.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.151 172.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 84.6 t60 -128.23 130.43 47.94 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.939 175.084 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -108.6 142.15 39.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.057 179.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 9.5 t0 -127.74 119.35 21.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.703 . . . . 0.0 110.889 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.512 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 58.4 Cg_endo -77.81 -27.76 5.7 Favored 'Trans proline' 0 N--CA 1.466 -0.112 0 C-N-CA 122.711 2.274 . . . . 0.0 112.325 -174.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.05 -39.23 89.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 177.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 98.6 p -97.16 -6.49 34.73 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.819 176.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.4 mtt180 56.35 36.09 26.94 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.885 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 90.2 m -128.09 139.94 52.23 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.128 -169.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.6 t -112.45 127.62 69.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.171 174.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.2 t -115.03 124.01 71.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.003 176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.2 p -132.82 139.98 48.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.038 -176.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.88 -165.35 6.03 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.507 177.664 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.13 114.95 5.1 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.59 -176.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.1 m -143.63 177.65 2.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.783 0.325 . . . . 0.0 111.133 -177.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 89.5 p -60.65 176.12 0.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.895 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -51.45 142.95 12.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.879 -170.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.2 -32.55 55.97 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.19 -176.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.7 -41.01 89.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.078 178.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.5 t-160 -66.57 -40.94 89.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.872 178.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 49.1 mm -66.31 -38.26 81.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.118 -179.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.607 ' O ' ' HG3' ' A' ' 63' ' ' PRO . . . -65.73 -36.72 84.39 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.069 174.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -63.12 -36.29 83.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.963 175.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 94.5 mt -64.96 -42.1 93.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.162 175.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.9 mt -61.48 -39.78 84.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.151 175.004 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 90.2 m -63.51 -37.45 87.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.148 171.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.67 -27.46 69.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.064 175.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.447 ' HB1' HG12 ' A' ' 18' ' ' VAL . . . -81.91 -6.94 59.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.139 175.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.02 16.62 46.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.55 172.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.504 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 88.7 m-85 -123.22 155.0 38.0 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.921 0.391 . . . . 0.0 110.913 -178.446 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -90.6 108.5 27.7 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-O 121.584 0.707 . . . . 0.0 111.162 -176.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.607 ' HG3' ' O ' ' A' ' 53' ' ' ALA . 83.3 Cg_endo -81.13 -17.31 9.32 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.642 2.228 . . . . 0.0 112.337 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.835 -178.595 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.071 0 CA-C-O 120.841 0.353 . . . . 0.0 111.089 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.96 114.97 0.39 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.504 -177.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.534 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 8.1 mp -93.65 135.71 34.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.802 0.334 . . . . 0.0 110.858 -178.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -129.3 129.45 44.89 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.89 -179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -129.7 142.86 50.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.858 177.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -110.16 121.67 45.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.775 173.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.0 t -131.19 109.45 16.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.125 -173.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.435 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 51.0 mm-40 -71.12 -32.16 68.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.874 -173.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -62.16 -21.33 64.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.822 -176.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.4 mtp -61.08 131.82 51.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.874 178.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.0 m -136.08 -44.87 0.64 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.113 -169.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -139.41 171.08 14.78 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 -174.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.88 -27.9 65.11 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.52 -176.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.5 t60 -57.69 -46.22 84.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.748 0.308 . . . . 0.0 110.841 176.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 93.7 m -63.06 -39.79 95.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.813 -178.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.494 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.47 -40.21 95.91 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.051 175.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.08 -39.31 96.23 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.519 179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -64.51 -42.2 94.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.825 0.345 . . . . 0.0 111.133 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 93.8 mt -62.46 -45.02 99.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.104 177.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 59.2 tttm -58.98 -46.15 88.84 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.937 176.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.05 -41.42 97.2 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.457 -177.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.82 -45.62 85.45 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.738 0.304 . . . . 0.0 111.101 -177.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.421 ' HA ' HG21 ' A' ' 55' ' ' ILE . 96.9 mt -70.01 -46.85 71.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.132 178.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.461 ' HA ' ' HB3' ' A' ' 30' ' ' ALA . 87.6 tt0 -61.5 -38.59 87.91 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.847 -176.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -67.77 -45.59 74.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.872 -177.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.8 p -90.18 -15.44 31.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.08 -171.145 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 90.5 t -124.11 119.24 26.53 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.564 0.697 . . . . 0.0 111.139 177.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.41 131.84 21.1 Favored 'Trans proline' 0 C--N 1.34 0.122 0 C-N-CA 122.692 2.261 . . . . 0.0 112.326 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.66 23.59 74.74 Favored Glycine 0 C--N 1.33 0.215 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.373 177.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.461 ' HB3' ' HA ' ' A' ' 24' ' ' GLU . . . -85.01 120.46 26.55 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.784 0.326 . . . . 0.0 111.154 -177.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -100.57 117.26 34.35 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.093 171.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 81.1 t -123.27 120.23 59.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.101 -178.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -120.05 113.46 20.54 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.892 172.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.494 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -116.03 144.92 43.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.09 -174.111 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -129.44 109.76 17.67 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.628 0.728 . . . . 0.0 110.828 179.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -73.55 -19.05 22.09 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.694 2.262 . . . . 0.0 112.423 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.29 -39.51 86.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.146 176.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 85.3 p -97.51 -10.84 24.56 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 173.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 64.6 41.2 5.52 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.876 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 63.4 p -127.62 159.39 34.83 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.162 -178.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.4 t -128.09 127.78 68.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.136 176.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 97.0 t -109.99 123.9 66.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.099 176.327 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.534 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 61.5 t -124.99 134.64 66.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.187 -173.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.28 -157.78 21.85 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.482 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.8 113.16 4.72 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.448 -178.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.9 m -146.45 177.13 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.887 0.375 . . . . 0.0 111.1 -175.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -63.33 176.07 0.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.912 176.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.67 129.77 1.94 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.9 -172.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.6 -32.83 59.38 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.132 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.47 -41.71 94.76 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.156 175.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -63.19 -40.06 96.43 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.869 175.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 45.1 mm -64.5 -39.64 86.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.121 179.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.97 -37.85 89.03 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.068 177.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.3 -37.17 86.33 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.915 175.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.421 HG21 ' HA ' ' A' ' 23' ' ' ILE . 90.6 mt -65.89 -43.15 93.1 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.158 177.085 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 96.3 mt -61.35 -39.93 84.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.116 176.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.9 m -63.72 -38.62 91.77 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.155 171.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.91 -25.0 67.7 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.132 176.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.55 -8.46 58.61 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 175.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.78 14.93 58.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.455 172.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -121.58 123.47 42.06 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.889 0.376 . . . . 0.0 110.93 -178.537 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.414 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 66.8 p -134.79 159.2 73.03 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.632 0.73 . . . . 0.0 111.111 -173.576 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.435 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 81.4 Cg_endo -70.44 157.35 59.34 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.71 2.274 . . . . 0.0 112.302 172.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.849 177.613 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.812 0.339 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 175.02 115.04 0.39 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.463 179.89 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.0 mp -105.38 140.06 39.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.818 0.342 . . . . 0.0 110.868 -179.095 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -132.18 131.67 42.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.84 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -129.98 145.41 51.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.875 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -111.57 125.16 53.63 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.821 175.451 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.03 107.28 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.12 -174.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.47 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 53.6 mm-40 -72.73 -37.37 67.77 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.792 -174.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -60.88 -24.57 66.05 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.924 -178.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . 0.414 ' HE1' HG22 ' A' ' 41' ' ' VAL . 56.0 ttm -61.76 129.41 40.88 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.756 178.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 86.0 m -132.75 -44.53 0.88 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.148 -169.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.1 p -137.04 174.63 10.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.926 -175.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.69 -27.96 67.23 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.527 -177.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -59.83 -47.62 85.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.802 0.334 . . . . 0.0 110.871 176.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.412 ' HG ' ' HE1' ' A' ' 61' ' ' TYR . 89.5 m -61.86 -39.55 92.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.895 -179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.403 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -64.13 -39.51 94.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.132 175.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.02 -38.86 95.94 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.517 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.26 -44.85 97.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.832 0.349 . . . . 0.0 111.12 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.1 mt -63.01 -45.21 99.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.13 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.7 -44.19 96.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.892 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.39 -41.32 94.51 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.421 -179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.63 -41.32 98.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.8 0.333 . . . . 0.0 111.166 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' HG21 ' A' ' 55' ' ' ILE . 97.7 mt -68.12 -48.87 72.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.138 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -62.75 -37.19 85.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.894 -175.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -65.12 -43.64 91.3 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.832 -177.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.8 p -94.94 -17.2 22.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.187 -171.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 73.0 t -124.1 112.82 28.28 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.588 0.709 . . . . 0.0 111.149 179.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -71.52 133.57 22.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.635 2.223 . . . . 0.0 112.301 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.99 21.27 78.7 Favored Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.507 176.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 123.9 29.25 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.763 0.316 . . . . 0.0 111.142 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.82 116.21 30.53 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.086 172.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 84.1 t -123.73 119.4 57.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.192 -177.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -119.97 108.45 14.33 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.814 172.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.403 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -112.1 143.41 43.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.064 -174.611 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.0 t0 -130.82 110.94 15.9 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.865 178.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -72.54 -20.35 23.66 Favored 'Trans proline' 0 C--N 1.343 0.248 0 C-N-CA 122.607 2.204 . . . . 0.0 112.356 -178.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.47 -38.7 84.83 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.056 177.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 68.9 p -99.72 -10.1 22.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.939 175.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 64.58 39.73 6.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.812 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 74.0 p -125.96 157.24 38.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.17 -176.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.414 HG22 ' HE1' ' A' ' 10' ' ' MET . 60.0 t -125.93 127.54 71.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.12 174.515 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.8 t -105.5 123.99 60.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 176.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.3 t -123.69 132.34 71.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.141 -170.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.64 -154.73 23.88 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.593 176.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -60.09 113.78 5.73 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.483 179.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.9 m -142.58 177.46 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.806 0.336 . . . . 0.0 111.131 -178.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.2 p -66.09 178.82 1.04 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.877 175.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.413 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.67 128.88 1.5 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.875 -174.078 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.67 -32.85 59.92 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.036 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -62.64 -40.32 96.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.112 175.732 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -66.97 -46.72 73.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.87 -177.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.486 ' HA ' HD12 ' A' ' 55' ' ' ILE . 15.9 tt -70.58 -26.76 29.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.113 -178.618 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.01 -38.84 92.26 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.057 171.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -67.16 -33.88 76.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.857 173.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.486 HD12 ' HA ' ' A' ' 52' ' ' ILE . 89.5 mt -64.67 -43.66 96.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.203 176.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.5 mt -60.41 -40.61 84.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.093 175.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 89.2 m -64.14 -37.97 89.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.144 172.305 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -24.51 67.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.15 178.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.3 -9.53 58.7 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.113 175.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 89.25 10.6 65.79 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.49 174.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.412 ' HE1' ' HG ' ' A' ' 15' ' ' CYS . 92.6 m-85 -122.2 117.79 27.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.944 0.402 . . . . 0.0 110.953 -177.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . 0.45 ' HB ' ' HD2' ' A' ' 63' ' ' PRO . 81.8 p -131.26 160.43 67.13 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.56 0.695 . . . . 0.0 111.11 -172.22 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.47 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 79.2 Cg_endo -68.8 160.3 50.21 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.714 2.276 . . . . 0.0 112.313 170.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 . . . . . 0 C--N 1.33 -0.281 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.9 178.475 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.117 0 CA-C-O 120.839 0.352 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.541 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.432 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -102.05 139.98 36.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.883 0.373 . . . . 0.0 110.845 -179.316 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.3 t -133.18 131.43 40.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.819 179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -127.68 141.72 51.53 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.891 177.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 86.3 t60 -112.03 125.31 53.95 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.84 174.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 58.6 t -122.53 110.79 27.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.179 -177.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -67.66 -32.94 73.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.885 -177.108 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -67.92 -23.85 65.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.877 -176.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 59.4 ttm -63.31 129.78 41.73 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.783 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 85.1 m -134.36 -44.99 0.76 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.151 -169.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.402 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.0 p -138.24 174.92 10.04 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.835 -173.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.98 -24.97 63.53 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.492 -176.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.402 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.4 t60 -63.54 -53.1 57.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.8 0.334 . . . . 0.0 110.874 175.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.3 m -61.32 -39.76 91.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.763 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.0 -40.23 95.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.093 175.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.99 -39.36 96.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.551 -179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -65.24 -46.63 90.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 120.87 0.366 . . . . 0.0 111.163 -178.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.0 mt -65.26 -46.26 91.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.148 178.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -59.01 -45.62 90.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.889 178.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.91 -40.34 93.52 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.395 179.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.43 98.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.739 0.304 . . . . 0.0 111.172 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.8 mt -67.59 -45.09 85.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.174 178.12 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -58.6 -43.97 89.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.947 179.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -75.97 -41.24 52.02 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.868 -174.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 93.8 m -77.09 -27.51 54.18 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.151 -171.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.425 ' HB ' ' HB2' ' A' ' 30' ' ' ALA . 95.6 t -116.79 111.64 41.07 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.609 0.719 . . . . 0.0 111.141 177.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.06 123.59 14.19 Favored 'Trans proline' 0 C--N 1.342 0.225 0 C-N-CA 122.663 2.242 . . . . 0.0 112.373 177.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.05 24.39 77.15 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.53 174.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 27' ' ' VAL . . . -75.86 136.89 40.16 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.858 0.361 . . . . 0.0 111.113 179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.46 110.93 22.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.067 169.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.91 132.22 24.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.155 -176.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 86.1 t60 -142.99 126.16 16.45 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.952 169.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.86 145.02 30.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.102 -176.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -127.48 110.53 21.0 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.829 179.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -75.73 -18.88 16.86 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.689 2.259 . . . . 0.0 112.397 -176.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.41 -39.06 88.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.085 178.34 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 p -100.34 -9.61 22.1 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.911 174.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.1 mtt180 65.3 39.52 5.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.849 179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 62.1 p -129.93 167.88 17.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.166 -177.143 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.7 t -125.01 129.99 73.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.081 173.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.4 t -102.65 119.74 51.45 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.15 177.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.432 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 87.5 t -124.08 128.6 74.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.147 -168.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -97.24 -140.69 11.5 Favored Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.481 176.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -56.19 115.13 5.76 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.457 177.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.9 m -148.5 174.64 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.855 0.36 . . . . 0.0 111.092 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.419 ' O ' ' C ' ' A' ' 48' ' ' ASP . 83.9 p -68.96 177.94 2.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.859 170.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.419 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.1 t0 -38.33 129.4 1.35 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.877 -173.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.03 -33.64 57.82 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.092 179.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.45 -39.58 84.07 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.064 175.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 22.1 t-160 -61.75 -40.54 95.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.849 175.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 46.5 mm -63.07 -41.25 92.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.098 -179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -64.89 -38.16 90.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.082 176.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.69 -34.71 78.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.902 176.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.429 HG21 ' HA ' ' A' ' 23' ' ' ILE . 87.7 mt -65.87 -40.26 87.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.178 176.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.4 mt -59.25 -40.52 81.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.16 174.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.5 m -64.06 -39.42 94.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.089 172.188 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.99 -25.26 67.79 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.073 176.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.84 -7.02 58.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 175.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.3 15.16 56.2 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.469 175.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -119.7 145.94 46.06 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.88 0.371 . . . . 0.0 110.96 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.6 m -109.22 115.23 56.89 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-O 121.561 0.696 . . . . 0.0 111.039 -178.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.81 155.03 48.93 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.702 2.268 . . . . 0.0 112.283 177.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 64' ' ' GLU . 88.7 tt0 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.902 -179.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.075 0 CA-C-O 120.831 0.348 . . . . 0.0 111.085 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.94 115.02 0.39 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.507 -178.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 77.9 mt -110.04 147.46 33.51 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.819 0.342 . . . . 0.0 110.821 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.2 t -130.86 131.93 44.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.812 175.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -128.91 139.05 52.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.915 -179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -110.29 120.43 42.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.748 174.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 61.6 t -124.76 109.04 21.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.224 -176.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 61.4 mm-40 -65.34 -30.02 70.82 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.849 -176.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -65.21 -25.48 67.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.881 -175.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.74 132.12 51.19 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.776 -179.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 88.0 m -136.33 -44.47 0.62 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.223 -168.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 28.9 p -140.44 171.79 13.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.913 -174.168 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.16 -26.96 61.99 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.503 -177.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 86.2 t60 -59.68 -47.04 87.18 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.832 0.348 . . . . 0.0 110.901 176.465 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 85.8 m -64.33 -39.33 93.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.839 -178.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.43 -39.92 94.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.113 174.615 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.06 -40.4 96.99 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.515 179.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 63.1 t -65.04 -45.22 95.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.841 0.353 . . . . 0.0 111.068 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 95.3 mt -64.9 -45.71 93.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.482 . . . . 0.0 111.08 177.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -60.69 -44.4 96.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.923 179.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.64 -41.38 96.01 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.502 -179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -42.03 98.94 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.8 0.333 . . . . 0.0 111.143 -179.228 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.439 ' HA ' HG21 ' A' ' 55' ' ' ILE . 93.2 mt -65.78 -48.07 83.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.187 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -65.13 -36.7 85.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.864 -177.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -65.34 -43.84 89.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.855 -177.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.5 p -91.55 -20.29 21.85 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.131 -174.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 76.3 t -127.49 107.41 21.03 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.617 0.722 . . . . 0.0 111.128 178.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -71.14 133.54 23.25 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.649 2.232 . . . . 0.0 112.34 -179.608 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.95 10.71 82.57 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.531 176.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -76.88 127.44 32.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.379 . . . . 0.0 111.058 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -96.93 115.67 27.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.13 174.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 91.3 t -121.74 120.93 63.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.064 -177.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -118.62 105.5 11.67 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.884 173.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -109.48 141.16 42.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.133 -171.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.404 ' HA ' ' HD2' ' A' ' 36' ' ' PRO . 65.4 t0 -130.58 105.45 15.77 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.64 0.733 . . . . 0.0 110.839 175.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 35' ' ' ASP . 56.6 Cg_endo -70.93 -25.58 23.03 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.552 2.168 . . . . 0.0 112.333 -179.054 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.56 -35.09 78.36 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.118 174.164 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 58.2 m -97.22 -5.49 36.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.808 177.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 96.5 mtt180 57.75 32.0 21.26 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.772 179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.2 m -131.85 139.17 48.74 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.099 -171.248 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.5 t -117.17 126.85 74.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.069 176.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.8 t -108.82 124.36 65.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.096 176.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.68 134.94 64.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.047 -169.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -78.96 -160.28 17.51 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.499 176.298 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.82 114.75 5.98 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.523 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 28.1 m -143.66 177.47 2.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.776 0.322 . . . . 0.0 111.169 -179.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.403 ' O ' ' C ' ' A' ' 48' ' ' ASP . 86.5 p -64.44 177.73 0.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.784 177.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.403 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.3 t0 -39.86 129.99 2.03 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.042 -0.527 . . . . 0.0 110.93 -173.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -54.83 -31.61 59.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.071 179.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.98 -40.64 96.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.17 175.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 86.5 t60 -67.01 -46.24 75.1 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.917 -177.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.482 ' HA ' HD12 ' A' ' 55' ' ' ILE . 16.0 tt -70.28 -26.92 30.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.134 -178.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.64 -38.48 89.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.083 170.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -67.66 -31.98 72.35 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.829 174.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 52' ' ' ILE . 84.5 mt -65.06 -41.73 92.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.092 175.374 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.7 mt -60.66 -40.18 83.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.133 174.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 93.9 m -63.76 -38.78 92.38 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.091 172.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -65.04 -25.88 68.02 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.105 176.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.85 -6.19 56.9 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.127 174.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.92 15.14 53.46 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.5 174.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.2 m-85 -119.95 143.92 47.74 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.991 0.424 . . . . 0.0 110.888 -178.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.2 m -116.72 119.83 35.1 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.544 0.688 . . . . 0.0 111.135 -176.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -71.71 152.58 59.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.699 2.266 . . . . 0.0 112.342 177.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 70.9 mm-40 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.86 -178.814 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.065 0 CA-C-O 120.787 0.327 . . . . 0.0 111.093 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.97 114.99 0.39 Allowed Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.435 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.541 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 11.2 mp -97.96 136.66 37.92 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.749 0.309 . . . . 0.0 110.958 -178.522 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.5 t -130.67 129.02 42.08 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.861 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 85.7 m-85 -128.29 141.13 51.53 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.912 177.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -111.27 120.13 41.23 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.833 171.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -125.74 108.98 20.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.142 -175.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 62.6 mm-40 -65.37 -29.35 70.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.888 -176.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 -66.73 -23.05 66.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.879 -174.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 95.7 mtp -62.46 133.17 54.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.831 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.9 m -136.74 -41.96 0.6 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.135 -168.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.0 p -144.77 170.26 16.45 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.88 -174.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -58.67 -27.19 61.1 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.545 -176.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -59.67 -47.6 84.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.822 0.344 . . . . 0.0 110.897 176.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 88.1 m -63.95 -38.72 92.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.825 -178.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.411 ' HB1' ' HB3' ' A' ' 34' ' ' ALA . . . -62.5 -39.5 93.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.081 173.751 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.04 -39.02 96.1 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.605 179.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -64.82 -45.97 93.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.842 0.353 . . . . 0.0 111.102 -178.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 92.9 mt -64.75 -43.73 96.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.171 176.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 61.6 tttp -58.4 -46.84 85.64 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.928 178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -66.26 -40.21 94.67 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.657 -0.782 . . . . 0.0 112.482 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.1 -43.26 98.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.808 0.337 . . . . 0.0 111.101 -177.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.0 mt -67.28 -46.69 83.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.243 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.42 -38.02 89.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.89 -177.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -67.96 -42.25 81.2 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.833 -177.065 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 80.9 p -92.33 -17.83 24.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.158 -173.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 87.2 t -124.87 116.69 26.14 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-O 121.563 0.696 . . . . 0.0 111.121 178.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -70.46 132.96 23.22 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.624 2.216 . . . . 0.0 112.399 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.27 21.74 77.29 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.43 176.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.99 124.6 29.28 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.737 0.303 . . . . 0.0 111.155 -178.412 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -101.3 117.87 35.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.047 171.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.5 t -124.63 121.5 61.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.176 -177.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.5 m-70 -119.99 112.07 18.7 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.889 171.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . 0.411 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . . . -114.86 145.06 42.58 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.067 -173.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -131.82 108.21 14.17 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.828 177.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.87 -19.57 23.41 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.681 2.254 . . . . 0.0 112.347 -177.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.07 -38.42 85.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.078 176.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 82.4 p -97.06 -10.77 25.43 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.849 173.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.93 38.7 6.28 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.8 178.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 79.8 p -126.48 157.64 38.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.151 -178.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 48.2 t -128.9 128.41 67.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.137 175.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 95.4 t -108.45 124.18 64.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.079 176.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.541 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.9 t -125.01 134.1 67.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.162 -172.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.88 -153.62 19.86 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.447 -179.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -61.86 111.33 3.84 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 -177.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 27.8 m -145.91 178.35 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.787 0.327 . . . . 0.0 111.195 -175.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.414 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.5 p -61.07 172.52 1.0 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.809 174.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.414 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.4 t0 -39.69 130.36 1.91 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -174.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.59 -32.7 52.14 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.066 178.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.99 91.03 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.09 174.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 19.9 t-160 -62.93 -40.05 96.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.915 175.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.8 mm -63.61 -40.06 87.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.138 179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.33 -38.28 89.66 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.076 176.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -65.84 -34.86 79.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.84 175.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 81.8 mt -65.2 -41.46 91.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.228 175.559 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 97.8 mt -60.24 -40.47 83.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.041 174.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.0 m -63.86 -39.44 94.2 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.097 172.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.92 -25.47 67.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.159 176.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.53 -5.58 56.92 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.101 175.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 92.68 15.03 54.29 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.467 174.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -119.14 144.22 46.77 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.028 0.442 . . . . 0.0 110.918 -178.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.3 m -116.08 120.25 35.61 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.611 0.72 . . . . 0.0 111.154 -176.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -71.39 154.97 60.75 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.72 2.28 . . . . 0.0 112.328 177.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . 0.415 ' O ' ' HG2' ' A' ' 64' ' ' GLU . 88.4 tt0 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.895 -178.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.06 0 CA-C-O 120.8 0.333 . . . . 0.0 111.113 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 174.99 114.97 0.39 Allowed Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.566 177.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.406 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 10.9 mp -108.52 141.98 39.6 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.764 0.316 . . . . 0.0 110.896 -178.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 48.4 t -137.39 132.27 33.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.844 178.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 93.9 m-85 -126.35 140.43 52.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.894 178.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 84.0 t60 -108.7 125.14 51.58 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.9 173.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.438 ' HB ' ' HG2' ' A' ' 10' ' ' MET . 96.1 t -128.52 120.92 53.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.148 -176.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -71.23 -29.97 65.79 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.898 -174.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -74.15 -9.25 58.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.878 -173.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . 0.438 ' HG2' ' HB ' ' A' ' 7' ' ' VAL . 88.6 mmm -62.0 124.73 21.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.804 177.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 87.3 m -133.85 -45.05 0.8 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.167 -168.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . 0.433 ' SG ' ' HB3' ' A' ' 14' ' ' HIS . 29.9 p -149.68 172.63 14.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -172.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.53 -27.49 63.63 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -177.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.433 ' HB3' ' SG ' ' A' ' 12' ' ' CYS . 85.6 t60 -59.91 -49.14 78.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.783 0.325 . . . . 0.0 110.828 176.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 86.5 m -62.26 -38.5 89.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.846 179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.75 -40.54 96.96 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.137 175.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.52 -38.52 95.84 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.659 -0.782 . . . . 0.0 112.556 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -65.88 -46.66 87.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.852 0.358 . . . . 0.0 111.165 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.3 mt -65.16 -47.28 88.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.211 177.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -59.03 -42.41 90.13 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.944 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -68.24 -39.65 87.97 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.672 -0.775 . . . . 0.0 112.454 177.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.0 -46.51 87.32 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.805 0.336 . . . . 0.0 111.127 -175.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 90.2 mt -68.72 -45.58 80.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.212 179.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -59.97 -40.04 87.7 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.878 179.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -71.86 -48.45 45.82 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.96 -175.375 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 82.2 p -86.79 -15.77 38.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.148 -167.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.456 ' CG1' ' HB2' ' A' ' 30' ' ' ALA . 68.1 t -122.23 117.61 29.3 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.598 0.714 . . . . 0.0 111.132 176.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -71.07 130.94 18.5 Favored 'Trans proline' 0 N--CA 1.466 -0.147 0 C-N-CA 122.661 2.241 . . . . 0.0 112.392 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.63 16.05 80.34 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.455 177.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.456 ' HB2' ' CG1' ' A' ' 27' ' ' VAL . . . -79.4 131.98 36.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.757 0.313 . . . . 0.0 111.053 -178.33 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -95.47 110.45 22.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.088 171.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 p -136.74 132.5 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.11 -178.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -144.78 126.36 15.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.868 168.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -103.63 145.37 30.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.1 -175.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -129.78 108.17 16.99 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.575 0.702 . . . . 0.0 110.827 179.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -77.58 -16.01 15.17 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.642 2.228 . . . . 0.0 112.386 -176.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -66.17 -39.33 89.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.027 178.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 61.6 p -99.68 -6.65 26.82 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.801 175.01 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.96 40.01 5.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.784 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 60.6 p -132.77 167.01 20.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.111 -178.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.2 129.52 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.12 174.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.4 t -103.28 119.89 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.159 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 91.5 t -124.67 129.16 73.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.151 -167.169 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -99.16 -140.05 11.22 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.558 176.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -55.95 116.66 7.56 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.55 176.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 19.2 m -148.96 174.32 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-O 120.783 0.325 . . . . 0.0 111.179 -177.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 48' ' ' ASP . 77.8 p -68.93 178.51 2.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.862 170.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 47' ' ' SER . 66.6 t0 -38.61 129.21 1.46 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.881 -176.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -53.78 -34.0 57.68 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.086 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.23 -41.51 93.25 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.155 176.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 21.5 t-160 -61.94 -41.6 98.15 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.884 175.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 39.6 mm -64.62 -40.05 87.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.171 -178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.06 -38.3 90.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.109 177.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -65.96 -37.03 84.96 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.885 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 88.0 mt -65.7 -41.66 90.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 178.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.74 -41.18 87.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 176.709 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 55.4 m -66.23 -36.13 82.23 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.183 172.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.72 -25.12 68.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.117 176.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.19 -9.29 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 175.207 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.05 12.68 59.93 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.785 -0.722 . . . . 0.0 112.526 174.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -122.01 109.7 14.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.935 0.398 . . . . 0.0 110.937 -178.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 97.7 m -137.19 131.33 17.64 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.615 0.722 . . . . 0.0 111.124 -175.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -66.71 154.97 72.61 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.731 2.287 . . . . 0.0 112.276 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.881 -178.943 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.771 0.32 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 115.05 125.06 3.93 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.512 179.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.571 HD13 ' HB1' ' A' ' 49' ' ' ALA . 41.9 tp -134.45 128.21 33.04 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.809 0.337 . . . . 0.0 110.946 179.659 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.7 t -107.55 116.98 32.92 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.006 0.432 . . . . 0.0 110.905 162.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 83.2 t80 -136.02 129.98 32.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.955 -169.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 65.2 t-80 -91.82 133.79 35.33 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.925 -177.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.672 ' HA ' ' HB3' ' A' ' 63' ' ' PRO . 91.5 t -123.15 123.86 68.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.162 -176.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -72.12 -39.45 68.82 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.878 179.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -91.07 49.69 1.67 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.91 -173.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 93.6 mmm -84.63 135.49 34.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.979 171.066 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -120.95 -62.29 1.46 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.135 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 29.8 p -133.11 175.59 9.25 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.92 -177.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.74 3.59 74.04 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.474 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -89.96 -5.62 56.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.778 0.323 . . . . 0.0 110.876 177.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 96.2 m -64.25 -25.68 68.17 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.823 175.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.83 -40.4 92.66 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.12 175.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -65.89 -40.9 95.67 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.62 -0.8 . . . . 0.0 112.488 177.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -64.74 -45.13 96.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.751 0.31 . . . . 0.0 111.15 178.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 94.7 mt -64.94 -43.37 96.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.095 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -57.16 -49.62 75.36 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.849 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -60.0 -40.95 97.67 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.524 -177.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.64 -41.26 92.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.739 0.304 . . . . 0.0 111.119 178.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 85.4 mt -67.8 -40.82 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.177 178.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 47.8 mm-40 -55.85 -30.6 61.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.825 -174.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -60.38 -40.93 92.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.993 -176.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 81.3 p -100.89 -25.06 14.23 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.089 -178.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 49.0 t -133.3 92.15 25.42 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.651 0.738 . . . . 0.0 111.151 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.76 136.49 38.96 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.652 2.235 . . . . 0.0 112.33 -178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.0 49.25 6.09 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.437 178.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.3 133.42 54.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.141 -178.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -98.41 123.17 42.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 178.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.1 t -120.34 122.58 68.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.156 178.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -122.74 116.52 23.89 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.879 174.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.45 144.68 44.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.082 -175.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -130.61 111.26 16.25 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.59 0.71 . . . . 0.0 110.95 177.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -76.33 -16.9 17.11 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.621 2.214 . . . . 0.0 112.362 -176.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.47 -38.24 77.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.062 175.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 92.0 p -96.59 -10.79 26.4 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.907 173.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 64.81 38.23 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.881 178.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.1 p -124.96 155.1 40.15 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.125 -176.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -126.93 129.0 71.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.108 174.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 96.9 t -110.14 124.59 67.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.136 176.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.9 t -121.18 131.72 72.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.168 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -74.56 -160.27 7.35 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.441 -177.379 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -54.93 116.49 6.79 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.489 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.606 ' CG2' HG13 ' A' ' 52' ' ' ILE . 15.1 m -145.15 171.09 5.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.878 0.37 . . . . 0.0 111.044 -176.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 48' ' ' ASP . 82.7 p -60.83 -178.47 0.1 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.828 173.029 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.445 ' C ' ' O ' ' A' ' 47' ' ' SER . 64.8 t0 -37.97 120.48 0.86 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.873 -171.086 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.571 ' HB1' HD13 ' A' ' 3' ' ' LEU . . . -56.81 -31.53 64.8 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.167 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.99 -43.34 99.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.112 178.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.1 t60 -68.53 -37.41 79.98 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.854 177.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.606 HG13 ' CG2' ' A' ' 46' ' ' VAL . 48.0 mm -65.05 -36.68 78.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.088 178.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.03 -37.58 88.08 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.029 175.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.47 -36.33 83.83 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.922 174.213 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.475 HD12 HD13 ' A' ' 52' ' ' ILE . 88.5 mt -65.04 -39.24 85.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.147 176.192 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 92.9 mt -60.95 -44.61 98.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.165 176.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 74.0 p -70.55 -25.39 63.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.138 177.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -64.95 -14.49 60.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.134 176.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -77.9 2.38 17.56 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.094 176.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 97.91 20.76 20.35 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.443 178.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 21.2 m-30 -101.67 141.94 33.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.966 0.412 . . . . 0.0 110.878 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 73.0 p -125.08 75.03 67.39 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.61 0.719 . . . . 0.0 111.08 177.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.672 ' HB3' ' HA ' ' A' ' 7' ' ' VAL . 72.4 Cg_endo -75.02 71.29 5.07 Favored 'Trans proline' 0 N--CA 1.465 -0.175 0 C-N-CA 122.727 2.285 . . . . 0.0 112.398 177.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.92 -178.83 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.802 0.335 . . . . 0.0 111.119 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 106.19 121.29 4.78 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.527 -178.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 87.8 mt -120.55 150.8 40.29 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.853 0.359 . . . . 0.0 110.951 -176.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 43.3 t -127.12 135.74 51.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.842 174.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -129.67 138.92 51.45 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.924 -176.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 99.2 m-70 -107.77 114.53 28.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.827 162.42 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 96.3 t -93.75 120.86 43.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.181 -172.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -69.65 -34.27 73.77 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -176.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -90.1 13.08 15.9 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.871 -174.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 62.7 tpp -66.46 127.48 32.49 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.983 176.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 90.6 m -119.9 -50.1 2.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.17 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 30.9 p -155.0 175.06 14.3 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.875 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.488 ' HA2' ' HG3' ' A' ' 36' ' ' PRO . . . -64.27 -21.51 66.35 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.441 -177.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -74.82 -31.6 61.74 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.773 0.32 . . . . 0.0 110.843 178.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.99 -32.76 57.44 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.876 174.537 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.31 -36.85 83.43 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 173.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -62.68 -40.36 99.08 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 175.521 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 76.9 t -63.42 -40.83 90.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.829 0.347 . . . . 0.0 111.218 176.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 90.0 mt -60.74 -44.96 98.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.097 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -59.33 -39.69 83.92 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.856 176.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -62.01 -41.35 99.67 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.475 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.41 ' HB1' HG13 ' A' ' 55' ' ' ILE . . . -62.43 -42.52 99.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.821 0.343 . . . . 0.0 111.099 175.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 97.8 mt -62.57 -45.68 98.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.081 179.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 53.3 tp10 -65.13 -34.21 77.85 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.863 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -60.26 -43.56 96.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.9 -177.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 33.2 m -87.42 -29.64 21.31 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.155 -178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -128.17 103.39 20.68 Favored Pre-proline 0 C--N 1.331 -0.236 0 CA-C-O 121.656 0.741 . . . . 0.0 111.077 -179.043 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -70.57 134.52 26.45 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.682 2.255 . . . . 0.0 112.336 179.246 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.46 22.49 72.82 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.497 178.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.83 137.45 36.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.125 178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -93.55 117.0 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.115 175.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 76.7 t -121.09 121.9 66.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.189 -176.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -116.62 105.06 12.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.857 174.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -111.85 135.93 51.82 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.092 -173.579 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 55.9 t0 -131.44 105.79 14.55 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.595 0.712 . . . . 0.0 110.895 174.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.488 ' HG3' ' HA2' ' A' ' 13' ' ' GLY . 57.3 Cg_endo -76.49 -24.38 10.59 Favored 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.65 2.233 . . . . 0.0 112.352 -176.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -67.97 -35.68 78.77 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.027 173.136 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 70.0 m -95.41 -4.51 45.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.887 176.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 71.0 mtp85 53.73 39.86 30.78 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.928 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 78.1 m -134.25 131.59 38.66 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.079 -175.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 67.1 t -121.28 124.37 71.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.089 177.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 99.7 t -113.51 122.49 67.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.171 177.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 50.5 t -122.43 135.03 63.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.096 -174.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.97 -158.46 5.55 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.502 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -58.17 120.18 20.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.473 -176.124 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.7 m -136.93 171.51 16.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.902 0.382 . . . . 0.0 111.077 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.43 ' O ' ' C ' ' A' ' 48' ' ' ASP . 80.3 p -65.68 -179.2 0.64 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.909 176.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.43 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.5 t0 -38.36 131.43 1.2 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.828 -174.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.03 -27.57 61.77 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.082 -177.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.01 -40.06 92.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.085 174.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 67.6 m170 -69.72 -44.13 70.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.83 -174.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 18.8 tt -69.15 -32.93 55.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.141 -178.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -70.23 -37.41 74.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.105 174.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 88.8 tt0 -66.24 -43.83 85.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.914 -177.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.41 HG13 ' HB1' ' A' ' 22' ' ' ALA . 10.5 tp -71.2 -32.08 46.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 -176.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 94.8 mt -65.22 -40.15 87.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.24 172.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 92.1 m -62.97 -37.0 85.36 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.129 171.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -63.49 -27.32 69.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.163 175.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -82.12 -4.94 57.98 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.104 176.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.94 15.15 55.1 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.465 175.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.548 ' O ' ' HD3' ' A' ' 63' ' ' PRO . 97.6 m-85 -113.9 142.32 46.26 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.975 0.417 . . . . 0.0 110.873 -179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 63.3 m -99.91 98.24 7.09 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.599 0.714 . . . . 0.0 111.07 -179.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.548 ' HD3' ' O ' ' A' ' 61' ' ' TYR . 93.1 Cg_endo -81.12 124.31 4.85 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.69 2.26 . . . . 0.0 112.309 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.5 tt0 . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.892 170.11 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.857 0.36 . . . . 0.0 111.062 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.92 55.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.49 -177.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.405 ' HB2' ' HB ' ' A' ' 43' ' ' VAL . 97.6 mt -93.21 138.55 31.5 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 110.97 178.536 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 47.1 t -133.37 132.72 41.55 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.824 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -126.93 132.01 50.97 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.832 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 85.3 t60 -108.92 122.72 47.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.928 174.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -114.39 114.56 47.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.124 -175.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.44 ' H ' ' HA ' ' A' ' 63' ' ' PRO . 62.9 mm-40 -65.63 -40.73 92.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.914 -176.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -73.71 -10.04 59.28 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' MET . . . . . . . . . . . . . 60.8 tpp -64.43 111.86 2.86 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.843 -173.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 76.1 p -135.11 -5.04 2.38 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.087 179.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' CYS . . . . . . . . . . . . . 42.5 t -139.85 140.18 36.48 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.878 -173.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -76.17 -10.41 85.35 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.469 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -63.0 -54.67 34.73 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.747 0.308 . . . . 0.0 110.854 176.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 89.7 m -65.67 -29.95 70.58 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.876 -179.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.04 -41.12 97.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 172.615 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -64.97 -37.13 93.9 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.586 172.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -62.09 -39.5 84.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.804 0.335 . . . . 0.0 111.113 176.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 89.0 mt -60.16 -46.53 94.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.161 176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -58.97 -45.52 90.36 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.985 177.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -65.4 -40.47 96.39 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.419 178.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.61 -42.47 95.51 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.794 0.33 . . . . 0.0 111.146 -179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 94.4 mt -65.01 -47.52 87.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.139 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 51.6 tp10 -63.22 -34.03 76.76 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.881 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -64.79 -41.71 95.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.931 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' THR . . . . . . . . . . . . . 73.4 p -86.35 -20.03 28.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.102 -174.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.421 ' O ' HG13 ' A' ' 27' ' ' VAL . 7.3 p -150.93 121.37 3.73 Favored Pre-proline 0 C--N 1.33 -0.249 0 CA-C-O 121.656 0.741 . . . . 0.0 111.101 172.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -75.92 144.64 27.55 Favored 'Trans proline' 0 N--CA 1.465 -0.187 0 C-N-CA 122.664 2.243 . . . . 0.0 112.356 -175.143 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.16 29.29 51.14 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.509 177.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.84 134.95 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.76 0.314 . . . . 0.0 111.069 -177.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ALA . . . . . . . . . . . . . . . -94.65 118.33 31.54 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.112 175.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 59.0 t -123.53 119.78 58.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.121 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -116.58 106.74 13.89 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.874 175.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -114.18 140.54 48.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 -172.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -136.77 110.94 9.48 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.607 0.718 . . . . 0.0 110.853 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -75.33 -17.09 19.12 Favored 'Trans proline' 0 C--N 1.341 0.134 0 C-N-CA 122.645 2.23 . . . . 0.0 112.351 -178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -69.48 -37.33 77.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.099 173.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 99.6 p -96.66 -4.08 41.57 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.822 175.444 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 74.7 mtm180 58.94 31.73 21.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.839 179.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 92.0 m -130.49 137.72 49.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 -170.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.6 t -121.63 129.13 75.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.084 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 94.0 t -106.21 125.76 61.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.073 176.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.405 ' HB ' ' HB2' ' A' ' 3' ' ' LEU . 58.0 t -124.02 129.91 74.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.148 -169.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -82.71 -156.7 20.81 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.477 178.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -57.74 114.97 6.17 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.51 -178.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 31.2 m -146.31 176.52 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 0.0 111.121 -176.358 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.437 ' O ' ' C ' ' A' ' 48' ' ' ASP . 84.3 p -64.66 173.48 2.18 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.868 174.311 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.437 ' C ' ' O ' ' A' ' 47' ' ' SER . 68.2 t0 -38.17 124.97 1.25 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -173.089 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -56.01 -29.79 60.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.071 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -42.44 95.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.286 -0.416 . . . . 0.0 111.079 176.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -67.14 -35.73 80.34 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.897 174.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 47.2 mm -62.01 -37.7 78.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.132 178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -65.12 -35.12 80.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.107 176.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -67.97 -42.87 80.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.956 -179.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 40.7 pt -75.2 -22.86 16.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.106 -178.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ILE . . . . . . . . . . . . . 74.2 mt -65.14 -42.48 94.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.173 166.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 71.5 m -62.19 -30.79 71.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.138 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -62.34 -20.59 64.53 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.036 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.06 -5.09 53.17 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.145 179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.12 -5.92 68.67 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.483 175.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 12.8 m-30 -110.0 135.35 50.97 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.028 0.442 . . . . 0.0 110.946 176.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 43.0 p -115.96 155.53 47.76 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-O 121.503 0.668 . . . . 0.0 111.168 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.44 ' HA ' ' H ' ' A' ' 8' ' ' GLU . 73.4 Cg_endo -77.49 -8.94 17.36 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.67 2.247 . . . . 0.0 112.369 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.855 -177.652 . . . . . . . . 0 0 . 1 stop_ save_